

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

AM

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/705, C12N 15/12, 15/63, 15/70, 15/79	A1	(11) International Publication Number: WO 99/48921 (43) International Publication Date: 30 September 1999 (30.09.99)
(21) International Application Number: PCT/US99 06573 (22) International Filing Date: 25 March 1999 (25.03.99) (30) Priority Data: 60/079,501 26 March 1998 (26.03.98) US (71) Applicants (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304 (US). N.V. ORGANON [NL/NL]; Weth. Van Eschstraat 1, P.O. Box 20, NL-5340 BH Oss (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): HSUEH, Aaron, J., W. [US/US]; 25 Ryan Court, Stanford, CA 94305 (US). HSU, Sheau, Yu [-/US]; Apartment 40, 234 Escuela Avenue, Mountain View, CA 94040 (US). LIANG, Shan-Guang [CN/US]; 438 Ventura Avenue #9, Palo Alto, CA 94306 (US). VAN DER SPEK, Petrus, Johannes [NL/NL]; Bremlaan 10, NL-5342 HM Oss (NL). (74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL MAMMALIAN G-PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS (57) Abstract Isolated nucleotide compositions and sequences are provided for LGR4, LGR5 and LGR7 genes. The nucleic acid compositions find use in identifying homologous or related genes; in identifying endogenous ligands for these receptors; in producing compositions that modulate the expression or function of its encoded protein; for gene therapy; mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity <i>in vivo</i> is used for prophylactic and therapeutic purposes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

NOVEL MAMMALIAN G-PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS

INTRODUCTION

5 Field of the Invention

The field of this invention is the G-protein coupled receptor family of proteins.

Background

Gonadotropins (Luteinizing hormone, LH; follicle stimulating hormone, FSH; chorionic gonadotropin, CG) and thyrotropin (TSH)) are essential for the growth and
10 differentiation of gonads and thyroid gland, respectively. These glycoprotein hormones bind specific target cell receptors on the plasma membrane to activate the cAMP-protein kinase A pathway.

The receptors for LH, FSH and TSH belong to the large G-protein-coupled, seven-trans-membrane protein family but are unique in having a large N-terminal extra-cellular
15 (ecto-) domain containing leucine-rich repeats important for interaction with large glycoprotein ligands. Studies suggest that in these receptors, the extra-cellular leucine rich repeat region serves as a "baseball glove" which efficiently catches its corresponding large hormone ligand and optimally orients it for interaction with the seven trans-membrane-helical domain of the receptor.

20 Because hormones and receptors play a prominent role in a variety of physiological processes, there is continued interest in the identification of novel receptors and their ligands, as well as the genes encoding the same.

Relevant Literature

References of interest include: el Tayar, N. "Advances in the Molecular
25 Understanding of Gonadotropins-Receptors Interactions," Mol. Cell. Endocrinol. (December 20, 1996) 125: 65-70; Bhowmick et al., "Determination of Residues Important in Hormone Binding to the Extracellular Domain of the Luteinizing Hormone/Chorionic Gonadotropin Receptor by Site-Directed Mutagenesis and Modeling," Mol. Endocrinol. (September 1996) 10: 1147-1159; Thomas et al., "Mutational Analyses of the
30 Extracellular Domain of the Full-Length Lutropin/Choriogonadotropin Receptor Suggest Leucine-Rich Repeats 1-6 are Involved in Hormone Binding," Mol. Endocrinol. (June 1996) 10:760-768; Segaloff & Ascoli, "The Gonadotropin Receptors: Insights from the

Cloning of their cDNAs." Oxf. Rev. Reprod. Biol. (1992) 14: 141-168; Braun et al.,
"Amino-Terminal Leucine-Rich Repeats in Gonadotropin Receptors Determine Hormone
Selectivity," EMBO J (July 1991) 10: 1885-1890; and Segaloff et al., "Structure of the
Lutropin/Choriogonadotropin Receptor," Recent Prog. Horm. Res. (1990) 46: 261-301.

5

SUMMARY OF THE INVENTION

Three novel mammalian G-protein coupled receptors having extra-cellular leucine
rich repeat domains, i.e. LGR4, LGR5 and LGR7, and polypeptide compositions related
thereto, as well as nucleotide compositions encoding the same, are provided. The subject
10 proteins, polypeptide and nucleic acid compositions find use in a variety of different
applications, including the identification of homologous or related genes; the production
of compositions that modulate the expression or function of the subject proteins; in the
identification of endogenous ligands for the subject orphan receptors; in the generation of
functional binding proteins for the neutralization of the actions of endogenous ligands; in
15 gene therapy; in mapping functional regions of the protein; and in studying associated
physiological pathways. In addition, modulation of the gene activity *in vivo* is used for
prophylactic and therapeutic purposes, and the like.

BRIEF DESCRIPTION OF THE FIGURES

- 20 Fig. 1 provides the nucleotide and amino acid sequence for human LGR4.
Fig. 2 provides the nucleotide and amino acid sequence for human LGR5.
Fig. 3 provides the nucleotide and amino acid sequence for human LGR7, long
form.
Fig. 4 provides the nucleotide and amino acid sequence for human LGR7, short
25 form.
Fig. 5 provides an alignment comparison of the long and short forms of LGR7.
Figs. 6 provides a comparison of deduced amino acid sequence of LGR4 and 5
cDNAs and those encoding FSH and LH receptors.

30

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Novel mammalian G-protein coupled receptors having extra-cellular leucine rich repeat regions (i.e. LGR4, LGR5 and LGR7) and polypeptide compositions related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and/or nucleic acid compositions find use in a variety of different applications, including the identification of homologous or related genes; for the identification of endogenous ligands for these novel receptors; the production of compositions that modulate the expression or function of the receptors; for gene therapy; for mapping functional regions of the receptors; in studying associated physiological pathways; for *in vivo* prophylactic and therapeutic purposes; as immunogens for producing antibodies; in screening for biologically active agents; and the like.

Before the subject invention is further described, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

CHARACTERIZATION OF LGR4, LGR5 AND LGR7

LGR4, LGR5 and LGR7 are novel mammalian receptors of the G-protein coupled, seven trans-membrane family of proteins, specifically the subfamily of G-protein coupled seven trans-membrane proteins which are characterized by the presence of extra-cellular leucine rich repeat regions. As such, these proteins have trans-membrane segments and extra-cellular regions similar to those found in the known LH, FSH, and TSH receptors. In other words, these proteins have both a G-protein coupled seven trans-membrane region

and a leucine rich repeat extra-cellular domain. The N-terminal extra-cellular domains of these proteins also show high homology with *Drosophila* Slit and Toll proteins having leucine rich repeats. These proteins are expressed in diverse tissues.

The human LGR4 gene has a nucleotide sequence as shown in SEQ ID NO:01.

- 5 The human LGR4 gene product has an amino acid sequence as shown in SEQ ID NO:02. LGR4 is expressed in a plurality of different tissue types, including ovary, testis, adrenal, placenta, liver, kidney and intestine.

The human LGR5 gene has a nucleotide sequence as shown in SEQ ID NO:03.

- The LGR5 gene product has an amino acid sequence as shown in SEQ ID NO:04. LGR5
10 has been found to be mainly expressed in muscle, placenta and spinal cord tissue.

- The human LGR7 gene encodes multiple splicing variants, each of which contains a multitude of cysteine-rich low density lipoprotein (LDL) binding motifs at the N-terminus in addition to the leucine rich repeat region. The longer forms of LGR-7 have a higher similarity than shorter forms of LGR-7 to snail LGR in the trans-membrane domain
15 and the N-terminal LDL binding domain. The overall structure of both the long and short forms of LGR-7 is similar to that of the LH receptor. The human LGR7 short form gene has a nucleotide sequence as shown in SEQ ID NO:05. The LGR7 short form gene product has an amino acid sequence as shown in SEQ ID NO:06. The human LGR7 long form gene has a nucleotide sequence as shown in SEQ ID NO:07. The LGR7 long form
20 gene product has an amino acid sequence as shown in SEQ ID NO:08. LGR7 is expressed in multiple tissues, including testis, ovary, prostate, intestine and colon.

IDENTIFICATION OF *LGR4*, *LGR5* AND *LGR7* SEQUENCES

- Homologs of *LGR4*, *LGR5* and *LGR7* are identified by any of a number of
25 methods. A fragment of the provided cDNA may be used as a hybridization probe against a cDNA library from the target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers.

- Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6×SSC (0.9 M sodium chloride/0.09 M
30 sodium citrate) and remain bound when subjected to washing at 55°C in 1×SSC (0.15 M sodium chloride/0.015 M sodium citrate). Sequence identity may be determined by

hybridization under stringent conditions, for example, at 50°C or higher and 0.1×SSC (15 mM sodium chloride/0.15 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided *LGR4*, *LGR5* and/or *LGR7* sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided sequences under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g., primate species, particularly human; rodents, such as rats and mice; canines; felines; bovines; ovines; equines; yeast; nematodes; etc.

Between mammalian species, e.g., human and mouse, homologs have substantial sequence similarity, e.g. at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* **215**:403-10. Unless specified otherwise, all sequence analysis numbers provided herein are as determined with the BLAST program using default settings. The sequences provided herein are essential for recognizing *LGR4*, *LGR5* and *LGR7*-related and homologous proteins in database searches.

LGR4, *LGR5* and *LGR7* NUCLEIC ACID COMPOSITIONS

Nucleic acids encoding *LGR4*, *LGR5* and *LGR7* may be cDNA or genomic DNA or a fragment thereof. The terms "*LGR4* gene," "*LGR5* gene" and "*LGR7* gene" shall be intended to mean the open reading frame encoding specific *LGR4*, *LGR5* and *LGR7* polypeptides, and *LGR4*, *LGR5* and *LGR7* introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene may be introduced into an appropriate vector for extra-chromosomal maintenance or for integration into a host genome.

The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, removed by nuclear
5 RNA splicing, to create a continuous open reading frame encoding an LGR4, LGR5 and LGR7 protein.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include the 3'
10 and 5' untranslated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic
15 DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

The sequence of the 5' flanking region may be utilized for promoter elements, including enhancer binding sites, that provide for developmental regulation in tissues
20 where *LGR4*, *LGR5* and/or *LGR7* is expressed. The tissue specific expression is useful for determining the pattern of expression, and for providing promoters that mimic the native pattern of expression. Naturally occurring polymorphisms in the promoter region are useful for determining natural variations in expression, particularly those that may be associated with disease.

25 Alternatively, mutations may be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems. Methods for the identification of specific DNA motifs involved in the binding of transcriptional factors are known in the art, *e.g.* sequence similarity to known binding motifs, gel retardation studies, *etc.* For examples, see Blackwell *et al.* (1995), *Mol. Med.* **1**:194-205; Mortlock *et al.*
30 (1996), *Genome Res.* **6**:327-33; and Joulin and Richard-Foy (1995), *Eur. J. Biochem.* **232**:620-626.

The regulatory sequences may be used to identify *cis* acting sequences required for transcriptional or translational regulation of *LGR4*, *LGR5* and/or *LGR7* expression, especially in different tissues or stages of development, and to identify *cis* acting sequences and *trans*-acting factors that regulate or mediate *LGR4*, *LGR* and/or *LGR7* expression. Such transcription or translational control regions may be operably linked to an *LGR4*, *LGR5* or *LGR7* gene in order to promote expression of wild type or altered *LGR4*, *LGR5* or *LGR7* or other proteins of interest in cultured cells, or in embryonic, fetal or adult tissues, and for gene therapy.

The nucleic acid compositions of the subject invention may encode all or a part of the subject polypeptides. Double or single stranded fragments may be obtained of the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc.* For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and may be at least about 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening probes, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other.

The *LGR4*, *LGR* and *LGR7* genes are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include an *LGR4*, *LGR5* or *LGR7* sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide

sequences, as genomic DNA or RNA, is well established in the literature and does not require elaboration here. DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the
5 subject DNA sequences. Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject
10 sequence is indicative of *LGR4*, *LGR5* and/or *LGR7* gene expression in the sample.

The sequence of an *LGR4*, *LGR5* or *LGR7* gene, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, *etc.* The DNA sequence or protein product of such a mutation will usually be substantially similar to the
15 sequences provided herein, *i.e.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions, deletions, or a combination thereof. Deletions may further include larger changes, such as deletions of a domain or exon. Other modifications of interest include epitope tagging, *e.g.* with the
20 FLAG system, HA, *etc.* For studies of subcellular localization, fusion proteins with green fluorescent proteins (GFP) may be used.

Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for site specific mutagenesis may be found in Gustin *et al.* (1993), *Biotechniques* **14**:22; Barany (1985), *Gene* **37**:111-23; Colicelli *et al.* (1985), *Mol. Gen. Genet.* **199**:537-9; and Prentki *et al.* (1984), *Gene* **29**:303-13. Methods for site specific
25 mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.* (1993), *Gene* **126**:35-41; Sayers *et al.* (1992), *Biotechniques* **13**:592-6; Jones and Winistorfer (1992), *Biotechniques* **12**:528-30; Barton *et al.* (1990), *Nucleic Acids Res* **18**:7349-55; Marotti and Tomich (1989), *Gene Anal. Tech.* **6**:67-70; and Zhu (1989), *Anal Biochem* **177**:120-4. Such mutated genes may
30

be used to study structure-function relationships of LGR4, LGR5 and/or LGR7, or to alter properties of the protein that affect its function or regulation.

LGR4, LGR5 and LGR7 POLYPEPTIDES

5 Also provided by the subject invention are LGR4, LGR5 and LGR7 polypeptide compositions. The term polypeptide composition as used herein refers to both the full length proteins as well as portions or fragments thereof. Also included in this term are variations of the naturally occurring proteins, where such variations are homologous or substantially similar to the naturally occurring protein, be the naturally occurring protein
10 the human protein, mouse protein, or protein from some other species which naturally expresses an LGR4, LGR5 or LGR7 protein, usually a mammalian species. A candidate homologous protein is substantially similar to an LGR4, LGR5 or LGR7 protein of the subject invention, and therefore is an LGR4, LGR5 or LGR7 protein of the subject invention, if the candidate protein has a sequence that has at least about 80%, usually at
15 least about 90% and more usually at least about 98% sequence identity with an LGR4, LGR5 or LGR7 protein, as measured by BLAST, supra. In the following description of the subject invention, the term "LGR4, LGR5 or LGR7-protein" is used to refer not only to the human LGR4, LGR5 or LGR7 protein, but also to homologs thereof expressed in non-human species, e.g. murine, rat and other mammalian species.

20 The subject gene may be employed for producing all or portions of LGR4, LGR5 and LGR7 polypeptides. By "LGR4 polypeptide/protein", "LGR5 polypeptide/protein," and "LGR7 polypeptide/protein" is meant an amino acid sequence encoded by an open reading frame (ORF) of *LGR4*, *LGR5* and *LGR7* genes, including the full-length native polypeptide and fragments thereof, particularly biologically active fragments and/or
25 fragments corresponding to functional domains, e.g. extra-cellular regions; and including fusions of the subject polypeptides to other proteins or parts thereof, e.g. chimeric proteins. For expression, an expression cassette may be employed. The expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control
30 of the transcriptional initiation region, and a transcriptional and translational termination

region. These control regions may be native to an *LGR4*, *LGR5* or *LGR7* gene, or may be derived from exogenous sources.

Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding
5 heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for the production of fusion proteins, where the exogenous fusion peptide provides additional functionality, i.e. increased protein synthesis, stability, reactivity with defined antisera, an enzyme marker, e.g. β -galactosidase, etc.

10 Expression cassettes may be prepared comprising a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region. Of particular interest is the use of sequences that allow for the expression of functional epitopes or domains, usually at least about 8 amino acids in length, more usually at least about 15 amino acids in length, to about 25 amino acids, and up to the complete open reading frame
15 of the gene. After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression.

LGR4, LGR5 or LGR7 polypeptides may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E.*
20 *coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, e.g. COS 7 cells, may be used as the expression host cells. In some situations, it is desirable to express the *LGR4*, *LGR5* or *LGR7* gene in eukaryotic cells, where the *LGR4*, *LGR5* or *LGR7* protein will benefit from native folding and post-translational modifications. Small peptides can also
25 be synthesized in the laboratory. Polypeptides that are subsets of the complete *LGR4*, *LGR5* or *LGR7* sequence may be used to identify and investigate parts of the protein important for function or to raise antibodies directed against these regions.

For production of the extracellular domain of the *LGR4*, *LGR5* or *LGR7* receptor, the anchored receptor approach as described in Osuga et al, Mol. Endocrinol. (1997) 11:
30 1659-1668 may be employed. Likewise, the chimeric receptor approach described in Kudo et al. J Biol. Chem. (1996) 271: 22470-22478 may be used.

Such peptides find use in the identification of endogenous ligands and in drug screening for agonists and antagonists using methods described in Osuga, *supra*. Solubilized extracellular domains find use as therapeutic agents, e.g. in the neutralization of the action of endogenous ligands.

5 With the availability of the protein or fragments thereof in large amounts, by employing an expression host, the protein may be isolated and purified in accordance with conventional ways. A lysate may be prepared of the expression host and the lysate purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. The purified protein will generally be at
10 least about 80% pure, preferably at least about 90% pure, and may be up to and including 100% pure. Pure is intended to mean free of other proteins, as well as cellular debris.

 The expressed LGR4, LGR5 and LGR7 polypeptides are useful for the production of antibodies, where short fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of
15 antibodies over the surface of the polypeptide. Antibodies may be raised to the wild-type or variant forms of LGR4, LGR5 or LGR7. Antibodies may be raised to isolated peptides corresponding to these domains, or to the native protein.

 Antibodies are prepared in accordance with conventional ways, where the expressed polypeptide or protein is used as an immunogen, by itself or conjugated to
20 known immunogenic carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. Both polyclonal and monoclonal antibodies may be produced. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and then screened for high affinity antibody
25 binding. The immortalized cells, *i.e.* hybridomas, producing the desired antibodies may then be expanded. For further description, see Monoclonal Antibodies: A Laboratory Manual, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to
30 further enhance the affinity of the antibody. Alternatives to *in vivo* immunization as a

method of raising antibodies include binding to phage "display" libraries, usually in conjunction with *in vitro* affinity maturation.

DIAGNOSTIC USES

5 The subject nucleic acid and/or polypeptide compositions may be used to analyze a patient sample for the presence of polymorphisms associated with a disease state or genetic predisposition to a disease state. Biochemical studies may be performed to determine whether a sequence polymorphism in an *LGR4*, *LGR* or *LGR7* coding region or control regions is associated with disease. Disease associated polymorphisms may include
10 deletion or truncation of the gene, mutations that alter expression level, that affect the activity of the protein, and the like.

 Changes in the promoter or enhancer sequence that may affect expression levels of *LGR4*, *LGR5* or *LGR7* can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer
15 strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, luciferase, chloramphenicol acetyltransferase, *etc.*, that provides for convenient quantitation; and the like.

 A number of methods are available for analyzing nucleic acids for the presence of
20 a specific sequence, *e.g.* a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express *LGR4*, *LGR5* or *LGR7* may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified
25 by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki, *et al.* (1985), *Science* **239**:487, and a review of techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–14.33. Alternatively, various methods are known in the art that utilize oligonucleotide
30 ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990),

Nucl. Acids Res. **18**:2887-2890; and Delahunty *et al.* (1996), *Am. J. Hum. Genet.* **58**:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.* fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.* ^{32}P , ^{35}S , ^3H ; *etc.* The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, *etc.* having a high affinity binding partner, *e.g.* avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods, and the sequence of bases compared to a wild-type *LGR4*, *LGR5* or *LGR7* sequence. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505 (the disclosures of which are herein incorporated by reference), may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in *LGR4*, *LGR5* or *LGR7* may be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting

deletions that may affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in LGR4, LGR5 or LGR7 proteins may be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded LGR4, LGR5 or LGR7 protein may be determined by comparison with the wild-type protein.

Antibodies specific for LGR4, LGR5 or LGR7 proteins may be used in staining or in immunoassays. Samples, as used herein, include biological fluids such as semen, blood, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid and the like; organ or tissue culture derived fluids; and fluids extracted from physiological tissues. Also included in the term are derivatives and fractions of such fluids. The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

Diagnosis may be performed by a number of methods to determine the absence or presence or altered amounts of normal or abnormal LGR4, LGR5 or LGR7 in patient cells. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. Cells are permeabilized to stain cytoplasmic molecules. The antibodies of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Alternatively, the secondary antibody conjugated to a fluorescent compound, *e.g.* fluorescein, rhodamine, Texas red, *etc.* Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, *etc.*

Diagnostic screening may also be performed for polymorphisms that are genetically linked to a disease predisposition, particularly through the use of microsatellite

markers or single nucleotide polymorphisms. Frequently the microsatellite polymorphism itself is not phenotypically expressed, but is linked to sequences that result in a disease predisposition. However, in some cases the microsatellite sequence itself may affect gene expression. Microsatellite linkage analysis may be performed alone, or in combination
5 with direct detection of polymorphisms, as described above. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994), *Genomics* **24**:225-233; Ziegle *et al.* (1992), *Genomics* **14**:1026-1031; Dib *et al.*, *supra*.

MODULATION OF *LGR4*, *LGR5* and *LGR7* GENE EXPRESSION

10 The *LGR4*, *LGR5* or *LGR7* genes, gene fragments, or the *LGR4*, *LGR5* or *LGR7* protein or protein fragments, are useful in gene therapy to treat disorders associated with *LGR4*, *LGR5* or *LGR7* defects. Expression vectors may be used to introduce the *LGR4*, *LGR5* or *LGR7* gene into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences.
15 Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, *e.g.* plasmid; retrovirus, *e.g.* lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a
20 period of at least about several days to several weeks.

The gene or *LGR4*, *LGR5* or *LGR7* protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992), *Anal Biochem* **205**:365-368. The DNA may be coated onto gold
25 microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang *et al.* (1992), *Nature* **356**:152-154), where gold microprojectiles are coated with the *LGR4*, *LGR5* or *LGR7* DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression of *LGR4*, *LGR5*, or
30 *LGR7* in cells. The anti-sense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or

nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, *e.g.* by reducing the amount of mRNA available for translation, through
5 activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the
10 antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It
15 has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996), *Nature Biotechnol.* 14:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence
20 for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in
25 the art (see Wagner *et al.* (1993), *supra*, and Milligan *et al.*, *supra*.) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

30 Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur;

phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoramidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The α -anomer of deoxyribose may be used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, *e.g.* ribozymes, anti-sense conjugates, *etc.* may be used to inhibit gene expression. Ribozymes may be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International patent application WO 9523225, and Beigelman *et al.* (1995), *Nucl. Acids Res.* **23**:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, *e.g.* terpyridylCu(II), capable of mediating mRNA hydrolysis are described in Bashkin *et al.* (1995), *Appl. Biochem. Biotechnol.* **54**:43-56.

25 GENETICALLY ALTERED CELL OR ANIMAL MODELS FOR LGR4, LGR5 AND LGR7 FUNCTION

The subject nucleic acids can be used to generate transgenic, non-human animals or site specific gene modifications in cell lines. Transgenic animals may be made through homologous recombination, where the normal *LGR4*, *LGR5* or *LGR7* locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

The modified cells or animals are useful in the study of *LGR4*, *LGR5* and/or *LGR7* function and regulation. For example, a series of small deletions and/or substitutions may be made in the host's native *LGR4*, *LGR5* or *LGR7* gene to determine the role of different exons. Of interest is the use of *LGR4*, *LGR5* or *LGR7* to construct transgenic animal
5 models for disease states. Specific constructs of interest include anti-sense *LGR4*, *LGR5* or *LGR7*, which will block *LGR4*, *LGR5* or *LGR7* expression, expression of dominant negative *LGR4*, *LGR5* or *LGR7* mutations, and over-expression of *LGR4*, *LGR5* or *LGR7* genes. Where an *LGR4*, *LGR5* or *LGR7* sequence is introduced, the introduced sequence may be either a complete or partial sequence of an *LGR4*, *LGR5* or *LGR7* gene native to
10 the host, or may be a complete or partial *LGR4*, *LGR5* or *LGR7* sequence that is exogenous to the host animal, *e.g.*, a human *LGR4*, *LGR5* or *LGR7* sequence. A detectable marker, such as *lac Z* may be introduced into the *LGR4*, *LGR5* or *LGR7* locus, where upregulation of *LGR4*, *LGR5* or *LGR7* expression will result in an easily detected change in phenotype.

15 One may also provide for expression of the *LGR4*, *LGR5* or *LGR7* gene or variants thereof in cells or tissues where it is not normally expressed, at levels not normally present in such cells or tissues, or at abnormal times of development. By providing expression of *LGR4*, *LGR5* or *LGR7* protein in cells in which it is not normally produced, one can induce changes in cell behavior, *e.g.* through *LGR4*, *LGR5* or *LGR7* mediated activity.

20 DNA constructs for homologous recombination will comprise at least a portion of the *LGR4*, *LGR5* or *LGR7* gene, which may or may not be native to the species of the host animal, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for
25 positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown *et al.* (1990), *Meth. Enzymol.* **185**:527-537.

30 For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, *e.g.* mouse, rat, guinea pig, *etc.* Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of leukemia

inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked
5 and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of
10 pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the
15 gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, *etc.*, *e.g.* to determine the effect of a candidate drug on *LGR4*, *LGR5* or *LGR7* or related
20 gene activation *etc.*

IN VITRO MODELS FOR *LGR4*, *LGR5* or *LGR7* FUNCTION

The availability of a number of components in the G-protein coupled receptor family, as previously described, allows *in vitro* reconstruction of the processes or systems
25 in which members of this family operate. Two or more of the components, such as the isolated receptor and a potential ligand therefore, may be combined *in vitro*, and the behavior assessed in terms of activation of transcription of specific target sequences; modification of protein components, *e.g.* proteolytic processing, phosphorylation, methylation, *etc.*; ability of different protein components to bind to each other. The
30 components may be modified by sequence deletion, substitution, *etc.* to determine the functional role of specific domains.

Drug screening may be performed using an *in vitro* model, a genetically altered cell or animal, purified LGR4, LGR5 or LGR7 protein, as well as fragments or portions thereof, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain. One can identify ligands or substrates that
5 bind to and modulate the action of LGR4, LGR5 or LGR7. Areas of investigation include the development of agents that beneficially counter abnormalities related to LGR4, LGR5 or LGR7 and the use of such agents in the therapy.

Drug screening identifies agents that modulate the activity of LGR4, LGR5 or LGR7 function in abnormal cells. Of particular interest are screening assays for agents
10 that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular interactions, such as GTP binding, *etc.*

15 The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function of LGR4, LGR5 or LGR7. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, *i.e.* at
20 zero concentration or below the level of detection.

In some embodiments, candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly
25 hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids,
30 purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

Of particular interest in certain embodiments are peptidic agents based on LGR4, LGR5 or LGR7, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain, where such agents neutralize the activity of endogenous LGR4, LGR5 or LGR7 ligands, e.g. hormones.

Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, e.g. magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin *etc.* For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts, neutral proteins, e.g. albumin, detergents, *etc.*, that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, *etc.*, may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.

Other assays of interest detect agents that mimic LGR4, LGR5 or LGR7 function. For example, an expression construct comprising an *LGR4*, *LGR5* or *LGR7* gene may be introduced into a cell line under conditions that allow expression. The level of LGR4, LGR5 or LGR7 activity is determined by a functional assay, as previously described. In one screening assay, the ability of candidate agents to inhibit or enhance LGR4, LGR5 or LGR7 function is determined. Alternatively, candidate agents are added to a cell that lacks functional LGR4, LGR5 or LGR7, and screened for the ability to reproduce LGR4, LGR5 or LGR7 activity in a functional assay.

The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment, *etc.* The compounds may also be used to enhance *LGR4*, *LGR5* or *LGR7* function. The inhibitory agents may be administered in a variety of ways, orally, topically, parenterally *e.g.* subcutaneously, intraperitoneally, by viral infection, intravascularly, *etc.* Topical treatments are of particular interest. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%.

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

25

EXPERIMENTAL

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (*e.g.* amounts, temperature, concentrations, *etc.*) but some experimental errors and deviations

30

should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

5 **Example 1. Identification of LGR4 and LGR5**

Human sequences related to the sea anemone and *Drosophila* glycoprotein hormone receptors were identified from the expression sequence tag database (dbEST) at the National Center for Biotechnology Information by using the BLAST server with the BLOSUM62 protein comparison matrix (Altschul SF *et al.*, Nucleic Acids Res (1997) 10 25:3389-3402). Human ESTs showing high homology to two non-overlapping regions of the gonadotropin receptors were identified. Clones AA312798 and AA298810 were found to encode transmembrane four to five of the putative receptor LGR4 whereas AA460529 and AA424098 encode transmembrane two to three of the putative receptor LGR5. Using these ESTs to further search the GenBank EST division database, 15 overlapping EST sequences were aligned to obtain the longest open reading frame (ORF) for these receptors.

Based on the longest human ORF, specific primers were designed for PCR amplification of LGR4 and LGR5 cDNA fragments from rat ovary and human placenta, respectively. After hybridization with labeled EST clones and confirmation of DNA 20 sequences by dideoxy DNA sequencing, specific receptor fragments isolated were used to design primers to prepare sub-cDNA libraries enriched with specific receptor cDNAs. For 5' extension, reverse transcription was performed using rat ovarian and human placenta mRNA preparations and receptor-specific primers. Following second strand synthesis, the enriched cDNA pool was tailed at 5'-ends with specific adaptor sequences to allow further 25 PCR amplification. For 3' extension, rat ovarian or human placenta mRNAs were reversed transcribed using oligo-dT, followed by second strand synthesis using receptor-specific primers and adaptor tailing. These mini-libraries were further used as templates for PCR amplification of upstream or downstream cDNAs specific for each receptor using internal primers. PCR products with a strong hybridization signal to each receptor cDNA 30 fragment were subcloned into the pUC18 or pcDNA3 vectors. After screening of these sublibraries based on colony hybridization using specific receptor probes, clones with 5'-

or 3'-sequences of the putative receptors were identified and isolated for DNA sequencing. As needed, the procedure was repeated up to three times to generate cDNAs encoding the complete ORF of each putative receptor for sequence analysis and for the expression of receptor proteins in eukaryotic cells. The entire coding sequences of each gene were also amplified with specific primers flanking the entire ORF in independent experiments. At least three independent PCR clones were sequenced to verify the authenticity of coding sequences. The nucleotide sequence of LGR4, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 1. The nucleotide sequence of LGR5, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 2.

Example 2. Comparison of deduced amino acid sequence of LGR4 and 5 cDNAs and those encoding FSH and LH receptors.

Sequence alignment of LGR4 and LGR5 with known human glycoprotein hormone receptors was performed and the results are shown in Fig. 6. Shaded residues are identical in at least two of the four receptor proteins shown.

Example 3. Expression pattern of LGR4 and 5 mRNA transcripts in different tissues.

For northern blot analysis, poly (A)⁺-selected RNA from different human tissues was hybridized with a ³²P-labeled cDNA probes. After washing, the blots were exposed to X-ray films at -70C for five days. Subsequent hybridization with a beta-actin cDNA probe was performed to estimate nucleic acid loading (8 h exposure). LGR4 was shown to be expressed in placenta, ovary, testis, adrenal, spinal cord, thyroid, stomach, trachea, heart, pancreas, kidney, prostate and spleen while LGR5 was shown to be expressed in the skeletal muscle, placenta, spinal cord, brain, adrenal, colon, stomach, ovary and bone marrow.

Example 4. Chromosomal localization of LGR4 and 5 in human.

Using genomic fragments of LGR4 (>100 Kb) and LGR5 (>100 Kb) as probes, chromosomal localization of these genes were detected using the FISH method to banded DNA in chromosomal 5q34-35.1 and 12q15, respectively.

5

Example 5. Identification of LGR7.

Analysis of EST databases has revealed a novel LGR closely related to a G protein-coupled receptor from pond snail (*Lymnaea stagnalis*, accession no. 481946). Because the snail G-protein coupled receptor shared the leucine-rich repeat ectodomain and seven
10 transmembrane region characteristics of mammalian LGRs, the novel EST sequence could encode either a homologue of snail receptor or a novel mammalian LGR. For the isolation of LGR7 cDNA, a Clontech Marathon-ready testis cDNA pool was used as the template for 5' and 3' RACE with adapter and gene-specific primers. Sequence analysis of the RACE products showed that LGR7 gene encode at least two splicing variants differ at the N-
15 terminus. The nucleotide sequence of the long variant, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 3; while the nucleotide sequence of the short variant, as well as the amino acid sequence of the ORF thereof, is provided in Fig. 4. Both variants contain a classical C-terminal 7-transmembrane region and a leucine-rich repeat ectodomain flanked by cysteine rich regions found in other mammalian LGRs. The
20 long form LGR7 contains extra 35 amino acids in the N-terminal cysteine rich region as compared to the short form LGR7. Of interest, analysis of the LGR7 ORF from either variant showed that its tertiary structure resembles that of mammalian LGRs instead of the snail receptor, which shares the greatest identity in the transmembrane region. These findings suggest that LGR7 and snail receptor diverged early during evolution and LGR7 perhaps
25 adopted new function in higher organisms.

Based on the LGR7 cDNA sequence, we further identified a human genomic DNA fragment (AQ053279) in the genomic survey sequence division of GenBank that contains part of the LGR7 gene. The authenticity of this genomic clone was confirmed by Southern blot hybridization and the genomic clone was used as the probe to identify the
30 chromosomal localization for LGR7 gene.

It is evident from the above discussion and results that three novel mammalian G-protein coupled receptors, as well as a nucleic acids encoding the same, are provided by the subject invention. The inventions described above find use in a variety of applications, including research and therapeutic applications.

5

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such a disclosure by virtue of prior invention.

10

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

15

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a mammalian protein selected from the group consisting of LGR4, LGR5 or LGR7.

5

2. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

10

3. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

15

4. An isolated nucleic acid according to Claim 1, wherein the nucleotide sequence of said nucleic acid has the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

20

5. An isolated nucleic acid comprising at least 18 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

25

6. An isolated nucleic acid comprising at least 50 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

30

7. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid having the nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the
5 complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

8. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a sequence of the isolated nucleic
10 acid according to Claim 1 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host.

9. A cell comprising an expression cassette according to Claim 8 as part of an
15 extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell, and the cellular progeny of said host cell.

10. A method for producing a mammalian protein selected from the group
20 consisting of LGR4, LGR5 and LGR7, said method comprising:

growing a cell according to Claim 9, whereby said mammalian protein is expressed; and

isolating said protein substantially free of other proteins.

25 11. A purified polypeptide composition comprising at least 50 weight % of the protein present as a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7, or a fragment thereof.

12. An antibody binding specifically to a mammalian protein selected from the
30 group consisting of LGR4, LGR5 and LGR7.

13. The antibody of Claim 12, wherein said antibody is a monoclonal antibody.

14. A non-human transgenic animal model for *LGR4*, *LGR5* or *LGR7* gene
function, wherein said transgenic animal comprises an introduced alteration in an *LGR4*,
5 *LGR5* or *LGR7* gene.

15. The animal model of claim 14, wherein said animal is heterozygous for
said introduced alteration.

10 16. The animal model of claim 14, wherein said animal is homozygous for said
introduced alteration.

17. The animal model of claim 14, wherein said introduced alteration is a
knockout of endogenous *LGR4*, *LGR5* or *LGR7* gene expression.

15

18. A method of screening a sample for the presence of a ligand for a receptor
selected from the group consisting of *LGR4*, *LGR5* and *LGR7*, said method comprising:
contacting said sample with a receptor selected from the group consisting
of *LGR4*, *LGR5* and *LGR7* or a mimetic thereof, and
20 detecting the presence of a binding event between said receptor and ligand
in said sample.

>Nucleotide sequence of LGR5 (total 2082 nucleotides) (SEQ ID NO:03)

CTACATCTCCATAACAATAGAAATCCACTCCCTGGGAAAGAAATGCTTTGATGGGCTCCACAGCCTAGAGACTTTAGATTTA
AATTACAATAACCTTGATGAATCCCCACTGCAATTAGGACACTCTCCAACCTTAAAGGAACTAGGATTCATAGCAACAAT
ATCAGGTCGATACCTGAGAAAGCATTGTAGGCAACCCCTTCTCTTATTACAATACATTTCTATGACAATCCCATCCAATTT
GTTGGGAGATCTGCTTTTCAACATTTACCTGAACTAAGAACACTGACTCTGAATGGTGCCTCACAAAATAACTGAATTTCTT
GATTTAACTGGAAGTCAAACCTGGAGAGTCTGACTTTAACTGGAGCACAGATCTCATCTCTTCTCTCAAACCGTCTGCAAT
CAGTTACCTAATCTCCAAGTGCTAGATCTGTCTTACAACCTATTAGAAGATTTACCCAGTTTTTTCAGTCTGCCAAAAGCTT
CAGAAAATTGACCTAAGACATAATGAAATCTACGAAATTAAGTTGACACTTTCCAGCAGTTGCTTAGCCTCCGATCGCTG
AATTTGGCTTGGAAACAAAATTGCTATTATTACCCCAATGCATTTTCCACTTTGCCATCCCCTAATAAAGCTGGACCTATCG
TCCAACCTCCTGTCGTCTTTTCTATAACTGGGTTACATGGTTTAACTCACTTAAATTAACAGGAAATCATGCCTTACAG
AGCTGGATATCATCTGAAAACCTTCCAGAACTCAAGGTATAGAAAATGCCTTATGCTTACCAGTGTCTGTCATTTGGAGTG
TGTGAGAATGCCTATAAGATTTCTAATCAATGGAATAAAGGTGACAACAGCAGTATGGACGACCTTCATAAGAAAAGATGCT
GGAATGTTTTCAGGCTCAAGATGAACGTGACCTTGAAGATTTCTGCTTGACTTTGAGGAAGACCTGAAAGCCCTTCATTCA
GTGCAGTGTTCACCTTCCCCAGGCCCTTCAAACCTGTGAACACCTGCTTGATGGCTGGCTGATCAGAATTGGAGTGTGG
ACCATAGCAGTTCTGGCACTTACTTGTAATGCTTTGGTGACTTCAACAGTTTTTCAGATCCCCTCTGTACATTTCCCCCATT
AACTGTTAATTGGGGTCACTGCGCAGCAGTGAACATGCTCAGGGAGTCTCCAGTGCCGTGCTGGCTGGTGTGGATGCGTTC
ACTTTTGGCAGCTTTGCACGACATGGTGCCTGGTGGGAGAATGGGGTTGGTTGCCATGTCAATGGTTTTTTGTCCATTTTT
GCTTCAGAATCATCTGTTTTCTGCTTACTCTGGCAGCCCTGGAGCGTGGGTTCTCTGTGAAATATTCTGCAAAATTTGAA
ACGAAAGCTCCATTTTCTAGCCTGAAAGTAATCAATTTGCTCTGTGCCCTGCTGGCCTTGACCATGGCCGAGTTCCCCCTG
CTGGGTGGCAGCAAGTATGGCGCCTCCCCTCTCTGCCTGCCTTTGCCTTTTGGGGAGCCCAGCACCATGGGCTACATGGTC
GCTCTCATCTTGCTCAATTCCCTTTGCTTCTCATGATGACCATTGCCTACACCAAGCTCTACTGCAATTTGGACAAGGGA
GACCTGGAGAATATTTGGGACTGCTCTATGGTAAACACATTGCCCTGTTGCTCTTCACCAACTGCATCCTAAACTGCCCT
GTGGCTTTCTGTCTCTCTCTCTTTAATAAACCTTACATTTATCAGTCTGAAGTAATTAAGTTTATCCTTCTGGTGGTA
GTCCCACCTTCTGCATGTCTCAATCCCCTTCTCTACATCTTGTTCAATCCTCACTTTAAGGAGGATCTGGTGAGCCTGAGA
AAGCAAACCTACGTCTGGACAAGATCAAAACACCCAAGCTTGATGTCAATTAACCTCTGATGATGTCGAAAAACAGTCTGT
GACTCAACTCAAGCCTTGGTAACCTTTACCAGCTCCAGCATCACTTATGACCTGCCTCCCAGTTCGGTGCCATCACCAGCT
TATCCAGTGACTGAGAGCTGCCATCTTCTCTGTGGCATTGTGCCATGTCTCTAA

>amino acid sequence of LGR5 (total 693 amino acids) (SEQ ID NO:04)

LHLHNNRIHSLGKKCFDGLHSLETLDLNNYNNLDEFPTAIRTLNKLKELGFHSNNIRSIPEKAFVGNPSLITIHFDNPIQF
VGRSAFQHLPELRLTLNLNGASQITEFPDLTGANLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNLLEDLPFSVCQKL
QKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLGNHALQ
SWISSENFPELKVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLDFFEDLKALHS
VQCSPSPGPFKPEHLLDGWLIRIGVWTIAVLALTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLTGVSSAVLAGVDAF
TFGSFARHGAWWENGVGCHVIGFLSIFASESSVFLTLAALERGFVSKYSKFKETKAPFSSSLKVIILLCALLALTMAAVPL
LGGSKYGASPLCLPLPFGEPTMGYVALILLNSLCFLMMTIAYTKLYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCP
VAFLSFSSLINLTFISPEVIKFILLVVVPLPACLNPLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMSINSDDVEKQSC
DSTQALVFTFTSSSITYDLPPSSVPSPAYPVTESCHLSSVAFVPCL

FIG. 2

3/8

>Final LGR7 (LGR7-Long variant) full length sequence (2467 nt) (SEQ ID NO:05).

GAAAGGAGGAAAGAAAAAAGAGGAATGGAAAGAGACAGAGAAAGGAAATGGGACTGGAAGGAGGGAGGACTGCTTT
 GTAAGTCTAAGATTGCAGACAGAAATAGCACACAAACACTGTGAGCTGTATGCGATTTCAGAAACCAAGACCAAATT
 TTGCTCACTTTTCATTAATCAGTTGCTCAGATAGAAGBAAATGACATCTGGTTCTGTCTTCTCTACATCTTAATTTT
 TGGAAATATTTTTCTCATGGGGGTGGACAGGATGTAAAGTGCTCCCTTGGCTATTTCCCTGTGGGAACATCACAA
 AGTGCTTGCCTCAGCTCCTGCACTGTAACGGTGTGGACGACTGCGGGAATCAGGCCGATGAGGACAACCTGTGGAGAC
 AACAAATGGATGGTCCATGCAATTTGACAAATATTTGCCAGTTACTACAAAATGACTTCCCAATATCTTTTGAGGC
 AGAAACACCTGAATGTTTGGTCCGTTCTGTGCCAGTGCAATGTCTTTGCCAAGGTCTGGAGCTTGACTGTGATGAAA
 CCAATTTACGAGCTGTTCCATCGGTTTCTTCAAATGTGACTGCAATGTCACTTCAGTGGAACTTAATAAGAAAAGCTT
 CCTCCTGATTGCTTCAAGAATTATCATGATCTTCAGAAGCTGTACCTGCAAAACAATAAGATTACATCCATCTCCAT
 CTATGCTTTTCAGAGGACTGAATAGCCTTACTAACTGTATCTCAGTCATAACAGAATAACCTTCCTGAAGCCGGGTG
 TTTTGAAGATCTTCACAGACTAGAATGGCTGATAATTGAAGATAATCACCTCAGTCGAATTTCCCCACCAACATTT
 TATGGACTAAATTTCTTATTCTCTTAGTCCTGATGAATAACGTCCTCACCCGTTTACCTGATAAACCTCTCTGTCA
 ACACATGCCAAGACTACATTGGCTGGACCTTGAAGGCAACCATATCCATAATTTAAGAAATTTGACTTTTATTTCCCT
 GCAGTAATTTAACTGTTTTAGTGATGAGGAAAAACAAATTAATCACTTAAATGAAAATACTTTTGCACTCTCCAG
 AAAGTGGATGAATTTGGATTTAGGAAGTAATAAGATTGAAAATCTTCCACCGCTTATATTCAAGGACCTGAAGGAGCT
 CTCACAATTGAATCTTTCTATAATCCAATCCAGAAAATTCAGCAAACCAATTTGATTATCTGTCAAACCTCAAGT
 CTCTCAGCCTAGAAGGGATTGAAATTTCAAATATCCAACAAAGGATGTTTAGACCTCTTATGAATCTCTCTCACATA
 TATTTTAAGAAATTCAGTACTGTGGGTATGCACCACATGTTTCGAGCTGTAAACCAACACTGATGGAATTTTCATC
 TCTAGAGAATCTCTTGGCAAGCATTATTTCAGAGAGTATTTGTCTGGGTTGTATCTGCAGTTACCTGCTTTTGAAACA
 TTTTGTCTATTTGCATGCGACCTTATATCAGGTCTGAGAACAGCTGTATGCCATGTCAATCATTTCTCTCTGCTGT
 GCGGACTGCTTAATGGGAATATATTTATTCGTGATCGGAGGCTTTGACCTAAAGTTTCGTGGAGAATACAATAAGCA
 TGCGCAGCTGTGGATGGAGAGTACTCATTGTGATGCTGAGTCTTTGGCCATTCTGTCCACAGAAGTATCAGTTT
 TACTGTTAACTTTCTGACATTGGAAAAATACATCTGCATTGTCTATCCTTTTAGATGTGTGAGACCTGGAAAATGC
 AGAACAATTACAGTTCTGATTCTCATTGGATTACTGGTTTTATAGTGGCTTTTCAATCCATTGAGCAATAAGGAATT
 TTTCAAAAATCTATGGCACCAATGGAGTATGCTTCCCTCTTCATTGAGAAGATACAGAAAGTATTGGAGCCCAGA
 TTTATTTCAGTGGCAATTTTTCTTGGTATTAATTTGGCCGATTTATCATCATAGTTTTTCTATGGAAGCATGTTT
 TATAGTGTTCATCAAAGTGCCATAACAGCAACTGAAATACGGAATCAAGTTAAAAAAGAGATGATCCTTGCCAAACG
 TTTTTCTTTATAGTATTTACTGATGCATTATGCTGGATAACCATTTTTGTAGTGAAATTTCTTTCACTGCTTCAGG
 TAGAAATACAGGTACCATAACCTCTTGGGTAGTGATTTTTATCTGCCCATTAACAGTGCTTTGAACCCAATTCTC
 TACTCTGACCAAGACCAATTAAGAAATGATTCATCGGTTTTGGGTATACTACAGACAAAGAAAATCTATGGA
 CAGCAAAGCTCAGAAAACATATGCTCCATCATTCTGCGGTGGAAATGTGGCCACTGCAGGAGATGCCACCTGAGT
 TAATGAAGCCGACCTTTTACATAACCCCTGTGAAATGTCACTGATTTCTCAATCAACGAGACTCAATTCCTATTCA
 TGA

>Final LGR7 (LGR7-long variant, total 757 amino acids)(SEQ ID NO:06)

MTSGSVFFYLIFGKYFSHGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCGDNNGWSMQFDKYFA
 SYYKMTSQYPFEAETPECLVGSVPVQCLCQGLELDCDETNLRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQK
 LYLQINKITSISIIYAFRGLNSLTKLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLRSISPPTFYGLNSLILLVLMN
 NVLTRLDPDKPLCQHMPRLHWDLEGNHIIHNLRLNLTFFISCSNLTVLVMRKNKINHLNENTFAPLQKLDLDELGLSNKIE
 NLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISNIQORMFRPLMNLISHIYFKFKQYCYGYPH
 VRSCPNPTDGISSLENLLASIIQRVFWVWSAVTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIG
 GFDLKFRRGEYNKHAQLWMESTHCQLVGSLLAILSTEVSVLLLTFLTLEKYICIVYPPFRVPRGKCRITITVLILIWITG
 FIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVFSYGSFMFYSVHQSAITATEI
 RNQVKEMILAKRFFIVFTDALCWIPIFVVKFLSLQLQVEIPGTITSWVVFILPINSALNPILYTLTTRPFKEMIH
 RFWYNRQRKSMDSKGQKTYAPSFIVWEMWPLQEMPELMPDLFTYPCMSLISQSTRLSYS*

FIG. 3

>Final LGR7 (LGR7-Short variant) full length sequence (3584 nt)(SEQ ID NO:07)

CTGTTTGTAACTGCTAAGATTGCGAGACAGAAATAGCACACACCCCTGTGAGCTGTATGCGATTGAGAAACCAAGA
 CCAATTTTGTCTCACTTTTATTAAATCAATTTCTCAGATAGAAAGGAAATGACATCTGTTTCTGTCTTCTTCTACATCT
 TAAATTTTGGAAATATTTTCTCATGCGCGGTGGACAGGATGTCAAGTGCTCCCTTGGCTATTTCCCTCTGGGAAC
 ATCACAAGTGCTTTCCTCAGCTCCTGCTACTGTAAACGGTGTGACGAGCTGCGGGAATCAGGCTGATGAGGACAACCTG
 TGTGTGTCTTTTGTCCAGTGTATGTCTTTTCCAGGTCTGGAACCTTGTACTGATGAAACCATTTATGAGTGTTCCTAT
 CCGTTTCTTCAAAATGTGACTGCAATGTCACTTCAGTGGAACCTTAATAAGAAAGCTTCTCCTCTATTGCTTCAAGAAT
 TATCATGATCTTCAGAAAGCTGACCTGCAAAACAATAAGATTACATCCATCTCCATCTATGCTTTGAGAGACTGAA
 TAGCCTTACTAACTGTATCTCAGTCATAACAGAATAACCTTCTGAAAGCGGGTGTTTTTGAAGATCTTCACAGAC
 TAGAATGCTGTATAATTGAAGATAATCACTCAGTCGAATTTCCCAACCAACATTTTATGGAATAAATCTCTTATT
 CTCTTAATCTGTATGAATAACCTCCTCAACCGTTTACCTGATAAACCTCTCTGTCAACACATSCCAAGACTACATTG
 GCTGGACCTTGAAGGCAACCATATCCATAATTTAAGAAATTTGACTTTTATTTCTGTCAGTAATTTAACTGTTTTAG
 TGATGAGGAAACCAAAATTAATCACTTAAATGAAATACTTTTGCACCTCTCCAGAACTGATGAATTSATTTA
 GGAAGTAATAAGATTGAAATTTTCCACCGCTTATATTCAAGGACCTGAGGAGCTGTCAATTAATCTTTTCTTA
 TAATCCAATTCAGAAATTCAGCAAAACCAATTTGATTATCTTGTCAAACCTCAAGTCTCTCAGCCTAGAAAGGATTG
 AAATTTCAAATATCCAACAAAGGATGTTTAGACCTCTTATGAATCTCTCTCACATATATTTTAAGAAATTCAGTAC
 TGTGGGTATTCACACATGTTTGCAGCTGTAAACCAAACTGATGGAATTTTCTCTCTAGAGAATCTCTTGGCAAG
 CATTATTCAAGAGTATTTGTCTGGGTGTATCTGCAGTTAAGCTGCTTTGGAAACATTTTGTCTATTTCATGCGAC
 TTATATCAGGTCTGAGAACAGCTGTATGCCATGTCAATCATTCTCTCTGCTGTGCCGACTGCTTAATGGGAATA
 TATTTATTCTGTATCGGAGGCTTTGACCTAAAGTTTCTGTGAGAAATACAATAAGCATGCGCAGCTGTGATGGAGAG
 TACTCATTGTCTGAGCTGTAGGATCTTTGGCCATTCTGTCCACAGAAGTATCAGTTTTACTGTTAACATTTCTGACAT
 TGGAAAAATACATCTGCATTGTCTATCTTTTAGATGTGTGAGACCTGGAAATGCAGAACAAATACATCTCTGATT
 CTCATTTTGTATTCTGTTTATAGTGGCTTTTCAATCCATTGAGCAATAAGGAATTTTCAAAAACTACTATGGCAC
 CAATGGAATATGCTTCCCTCTTCAATTCAGAAAGATACAGAAAGTATTGGAGCCAGATTTATTAGTGGCAATTTTCT
 TTGGTATTAATTTGGCCGCTTTATCATCATAGTTTTTCTATGGAAGCATGTTTTATAGTGTTCATCAAGTGCC
 ATAACAACAACCTGAAATACGGAATCAAGTTAAAAAGAGATGATCCTTGCCAAACGTTTTTCTTTATAGTATTTAC
 TGATGCATTATGCTGGATACCCATTTTGTAGTGAAATTTCTTTCACTGCTTCAGGTAGAAATACCAGGTACCATAA
 CCTCTTGGGTAGTGATTTTATTCTGCCCATTAAACAGTGCTTTGAACCCAATTTCTCTATACTCTGACCACAAGACCA
 TTTAAAGAAATGATTTCATCGGTTTTTGGTATAACTACAGACAAAGAAATCTATGGACAGCAAAAGGTGAGAAACATA
 TGCTCCATCATTCTGCTGGGTGAAATGTGGCCACTGCAGGAGATGCCACCTGAGTTAATGAAGCGGACCTTTTCA
 CATACCTCTGTGAAATGTCACTGATTTCTCAATCAACGAGACTCAATTCCTATTTCATGACTGACTCTGAAATTCATT
 TCTTCTGAGAGAATACTGTGGGGGTGCTTTCATGAGGGATTTACTGGTATGAAATGAATACCACAAAATTAATTTAT
 AATAATACTAAGATAAATATTTTACAAGGACATGAGGAAAAATAAAATGACTAATGCTCTTACAAAAGGAAGTAA
 TTATATCAATAATGTATATATATTAGTAGACATTTTGCATAAGAAATTAAGAGAAATCTACTTCAGTAACATTTCATT
 CATTTTCTAACATGCATTTATTGAGTACCCACTACTATGTGCATAGCATTGCAATATAGTCTGGAAGTAGACAGT
 GCAGAACCTTTCAATCTGTAGATAGTGTTTAAATGACAAAAGACTATACAAAGTCCATCTGCAGTTCTAGTTTAAAG
 TAGAGCTTTACCTGTCTATGTGCATCAGCAAGAATCATAGGCACCTTTAAATAAAGGTTTAAAGTTTGTGAATACTCA
 GTGATTTTGCATCATAGAAAATGTCTGACTGTTTGCAAAATAATATTCTGTTTTAAGAATCCATCTTACCTCTCTTT
 AAGTTTCTACATCTGTAGAGCCCAACACAACATATTATTACTAAAAAGATGCTTTGTGCTAGAAACTCAAAACAGCA
 CTCTTTTGTGCACTTCTGCCCAGTTTTCTCTTTGCTTTAAATGAACATCATCATATGGAATTTGGAATAGGAGAGTA
 TGAGTACGCGCAGAGAAGTGGATCAGAAAACTAGAATGAGGATAAACATTTACATTAGTGGAAACTCCTGAAATAAA
 TCCTTGATTTGTGAGTTAACTGATTTTCAACAAGGATGCCAAGACAAAAGGCTTTTCAACAAACCGTCTGTGTTTTA
 AGAACAGACCTAAGTGGTTTTAATTCACCCACTTTAGATGGGTGAATGTTATGGTGTGTGAAATATCTCAGTAAAGCA
 GTTAAAGGAAAAGAGCTGGAATGCACTGATTTCAGGAACCTAATTTTCAAGGAAGGAAAGGTCTGTATGTACACATTT
 CACTTTAAGCAGAAAATCTTTCTTCAAGAAATGACTTTACTTTCTCTTTGCACTGCCAGCACGTGAGATACTAATTT
 TTTAAGTATTTGTTCTCTCTAGTCTCTACGTTTATTAGNATTTTTGCTTTTCAATATGTGAAACCTTTAAGCAGGAG
 AAGAAAATGTTTTTCAATAGTTTTCAATAACNCCAAAATGTTTGCACACAAAAATACTGGAATCNAAACATAATGC
 CCTTATTGAATATATAGTTGTATAGNTTTGTTCTGAAAACCC

>Final LGR7-S ORF (722 amino acids) (SEQ ID NO:08)

MTSGSVFFYILIFGKYFSGGGQDVKCSLGYPFCGNITKCLPQLLHCNGVDDCGNQADEDCNVVVLCCQMSLPGLEL
 DWMKPFTSVPSVSSNVTAMSLQWNLRKLPPDCFKNYHDLQKLDLQNNKITSISIYAFRGLNSLTKLYLSHNRIITFL
 KPGVFEDLHRLEWLIIEDNHLRSISPPTFYGLNSLILLVLMNVLTRELDPKPLCQHMPLRLHWDLEGNHINLRLNLT
 FISCSNLTVLVLRKNIQHNLNENTFAPLQKLDLQKLDLQNNKITSISIYAFRGLNSLTKLYLSHNRIITFL
 FLKSLSLLEGIEISNIQRMFRPLMNLSHIYFKKFQYCYGYPHVRSCPNPDGISSLENLLASIIQRFVFWVSAVTC
 FGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGVFDLKRGEYNKHAQLWMESTHCQLVGSLLAILSTE
 VSVLLLTFLTLEKYICIVYPFRVPRPGKCRITITVLILILWITGFIYAFIPLSNKEFFKNYYGTNGVCFPLHSEDTEI
 GAQIYSVAIFLGINLAAFIIVFSYGSMPFYSVHQSATATEIRNOVKKEMILAKRFFFIVFTDALCWIPFIVVKFLS
 LLQVEIPGTITSWVIFILPINSALNPILYTLTTRPFKEMIHFRFWYNYRQRKSMDSKGQKTYAPSFIVWEMWPLQEM
 PPELMKPDFLTYPCEMSLISQSTRNLNSYS*

5/8

>Alignment of LGR7-L with LGR7-S

Query=LGR7-L

Sbjct=LGR7-S

```

Query: 1  MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYPFCGNITKCLPQLLHCNGVDDCGNQADE 60
          MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYPFCGNITKCLPQLLHCNGVDDCGNQADE
Sbjct: 1  MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYPFCGNITKCLPQLLHCNGVDDCGNQADE 60

Query: 61  NCGDNNGWSMQFDKYFASYKMTSQYPFEAETPECLVGSVPVQCCLCQ---GLELDCDETN 117
          NC                               V V C C      GLELD  +
Sbjct: 61  NC-----VVVLCQCMSLPGLELDWMKP- 82

Query: 118 LRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIIYAFRGLNSLT 177
          +VPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKL LQNNKITSISIIYAFRGLNSLT
Sbjct: 83  FTSVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLDLQNNKITSISIIYAFRGLNSLT 142

Query: 178 KLYLSHNRIITFLKPGVFEDLHRLEWLIIEDNHLRSRISPPTFYGLNSLILLVLMNNVLT 237
          KLYLSHNRIITFLKPGVFEDLHRLEWLIIEDNHLRSRISPPTFYGLNSLILLVLMNNVLT
Sbjct: 143 KLYLSHNRIITFLKPGVFEDLHRLEWLIIEDNHLRSRISPPTFYGLNSLILLVLMNNVLT 202

Query: 238 PDKPLCQHMPRLHWLDLEGNIHNLRLNLTIFISCSNLTVLVMRKNKINHLNENTFAPLQKL 297
          PDKPLCQHMPRLHWLDLEGNIHNLRLNLTIFISCSNLTVLVMRKNKINHLNENTFAPLQKL
Sbjct: 203 PDKPLCQHMPRLHWLDLEGNIHNLRLNLTIFISCSNLTVLVMRKNKINHLNENTFAPLQKL 262

Query: 298 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN 357
          DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN
Sbjct: 263 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN 322

Query: 358 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRFVFWVWSA 417
          IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRFVFWVWSA
Sbjct: 323 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRFVFWVWSA 382

Query: 418 VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKRGEYNKHAQ 477
          VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKRGEYNKHAQ
Sbjct: 383 VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKRGEYNKHAQ 442

Query: 478 LWMESTHCQLVGLAILSTEVSVLLLTFLTLEKYICIVYPPFRCVRPGKCRITITVLILIWI 537
          LWMESTHCQLVGLAILSTEVSVLLLTFLTLEKYICIVYPPFRCVRPGKCRITITVLILIWI
Sbjct: 443 LWMESTHCQLVGLAILSTEVSVLLLTFLTLEKYICIVYPPFRCVRPGKCRITITVLILIWI 502

Query: 538 TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIVF 597
          TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIVF
Sbjct: 503 TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIVF 562

Query: 598 SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPFVVKFSLSLQVEI 657
          SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPFVVKFSLSLQVEI
Sbjct: 563 SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPFVVKFSLSLQVEI 622

Query: 658 PGTITSWVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF 717
          PGTITSWVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF
Sbjct: 623 PGTITSWVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF 682

Query: 718 IWVEMWPLQEMPPPELMKPDFTYPCEMSLISQSTRLNSYS 757
          IWVEMWPLQEMPPPELMKPDFTYPCEMSLISQSTRLNSYS
Sbjct: 683 IWVEMWPLQEMPPPELMKPDFTYPCEMSLISQSTRLNSYS 722

```

FIG. 5

FIG. 6

LGR4 MPGPLGLLCFLALGLLGSAGPSGA
LGR5 MDTSRGLGVLLSLPVLLQLATG
LHR MKQRFSAQLLKLKLLQLQPPLPRA
FSHR MALLVLSLLAFLSLGSG
TSHR MRPADLLLOLVLLLDLPDLGG

LGR4	APPL	AA-P	S	DGDR----	RVD	SGKGLTAVPEGLSAFTQA
LGR5	GSSPRSGVLLRG	P-TH	H	EPDGRMLLRVD		SDLGLSELPSNLSVFTSY
LHR	LREAL	P-EP	N	VPDG--	ALR--	PGPTAGLTR
FSHR		HHRI	H	SNRVFL----		QESKVEIPISDLPRNAIE
TSHR	MG	SSPP	E	HOED--	FRVT	KDIORIPSLPPSTOT

	←—————→ ←—————→	
LGR4	DISMNNITQLPED KSFPPLEELQLAGN -- SL HPKALSG KE KVLTLO -- Q	
LGR5	DLSMNNISQLLPNPLPSLHFLEELRLAGNA-- TY PKGA TG YS KVLMLO -- Q	
LHR	SFLAYLPVKVIPSQ RGLNEVIKIEISQI S- ER EANA DN LN SEILIQ TK -	
FSHR	RFLVTLKLRTVIQKG SGFGDLEKIEISQN V- EV EADV SN PK HEIRIEKAN -	
TSHR	KLIETHLRITPISH SNLPNSRIYVSI- VT OOLESYS YN SKVTHIEIR TR -	

LGR4	RTV-	SE	IHG	SA	QS	RLDA	H-	TSV	EDS--	FEGLVQLRH	WLD	S-L-	EV	VR
LGR5	RHV-	TE	LQN	RS	QS	RLDA	H-	SYV	P-SC-	FSGLHSLRH	WLD	A-L-	E	VQ
LHR	RYIE	-G	FIN	PG	KY	SIC-	TG	RKF	DVTKVFSES	ENFI-	EIC	LHI-	T	GN
FSHR	LYIN	-E	FQN	PN	QY	LIS-	TG	KHL	DVHK-	IHSLOKVL-	DIQ	INIH	-	ERN
TSHR	TYID	-D	LKE	PL	KF	GIF-	TGLKMF	DLTK-	VYSTD	IFFEI	EIT	PYM-	S	VN

LGR4	PLSN	P-TLQA	T	AL	NISSIPDF	T	LSS	VV	H	HN	K-IKSLSQHC	D	LDN-LE	
LGR5	A	RS	S-ALQAMT	AL	KIHHPIDY	G	LSSWV	V	H	HN	R-IHSLGKKC	D	LHS-LE	
LHR	A	QGMN	NESVT	K	YG	GFEVEQSH	-	GTT	TS	E	KE	VHLEKMHNGA	R	A-TGPK
FSHR	S	VG	SFESVI	W	NK	GIQEIHCN	-	GTQ	DE	N	SD	NNLEELPNVDV	H	A-SGPV
TSHR	A	QG	CNETLT	K	YN	GFTSVOGY	-	GTK	DAVY	NK	KYLTVIDKDA	G	VYSGPV	

LGR4	T	LNYYNYLDEF	Q-AIKA	PS	KELGFHSNSISVI	D-GA	GGNPL	RTIH	-	DNPLS
LGR5	T	LNYYNNLDEF	T-AIRT	SN	KELGFHSNNIRSI	E-KA	VGNPS	ITIH	F-	DNPIQ
LHR	T	ISSTKLIQL	SYGLESIQ	R	ATS-SYSLKKL	SRET	V-N--	LEAT	T	----
FSHR	I	ISRTRHLSL	SYGLEN	KK	R-ARSTYN-LKKL	TLEKLVA	---	MEAS	T	----
TSHR	L	VSOTSVTAL	SKGLEH	KE	I-ARNTWT-LKKL	LSLS	LH--	TRAD	S	----

```
LGR4 FVGNSAFHNLSDLHCLVIRGASLVQWFPNLTGTVHLES�LTGTGISSIPDDLQCNQKML
LGR5 FVGRSAFQHLPELRTLTŁNGASQITEFPDLTGATANLES�LTGAQISSLPQTVCNQLPNL
LHR -----
FSHR -----
TSHR -----
```

7/8

LGR4 RTLDLSYNNIRDLPSPNGCRALBEEISLQRNQISLIKENTFQGLTSLRILDLSRNLIREIH
 LGR5 QVLDLSYNNLLEDLPSPFSVCQKLOKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKAIIH
 LHR -----
 FSHR -----
 TSHR -----

LGR4 SGAFAKLGTITNLDVSFNELTSFPTEGLNGLNQLK
 LGR5 PNAFSTLPSTLIKLDLSSNLLSSFPITGLHGLTHLK
 LHR -----
 FSHR -----
 TSHR -----

C-flank cysteine-rich sequence

LGR4	LVGNFKLKDALAARDFANLRSLSV	YAYQ	WGCDSLCKLNTEDNSPQEHSVTKEKGA
LGR5	LTGNHALQSLISSENFPELKVIEM	YAYQ	GVCENAYKISNQWNKGDNSSMDDLHKK
LHR	-----	--SH	RNLPTKEQNFSHSISENFSKQCESTVR
FSHR	-----	--SH	ANWRRQISELHPICNKSILRQEVDMYT
TSHR	-----	--SH	KNQKKIRGILESIMCNESMQSLRQRK

LGR4	TDAANVTSTAENE	HS	-----
LGR5	DAGMFQAQDERDL	DF	-----
LHR	KVSNKTLYSSMLA	SE	-----
FSHR	QTRGQRSSLAEDN	SS	-----
TSHR	SVNALNSPLHQEY	ENLGDSIVGYKEKSKFQDTHNNAHYVVFEEQEDEIIGFGQELKNP	

LGR4	-----	QIIH	T	STGA	K	YLLGSWMI
LGR5	-----	LLDFEEDLKALHSVQ	S	SPGP	K	HLLDGWLI
LHR	-----	LSGWDYEGFCLPKTPR	-	A	EPDA	N
FSHR	YSRGFDMTYTEFDYDL	CNEVVDVT	S	KPDA	N	DIMGYNIL
TSHR	QEETLQAFDSHYDYTCGDS	EDMV	T	KSDE	N	DIMGYKFL

Transmembrane

	<u>TM 1</u>										<u>TM 2</u>															
LGR4	LTV	F	FLV	LLF	LL	ILTVFA	CSS	PASKL	FIGLIS	SVSNLLM	IYT	GILTFL	AVSW													
LGR5	IGV	T	AV	LTC	AL	TSTVFR	PLYIS	PIKL	IGVIA	AVNMLT	VSSAVL	G	AF	F												
LHR	VLI	L	NI	IMG	MT	LFVLLT	RYK	TVPRF	MCNLS	FADFCM	LYLLLI	S	SQ	K												
FSHR	VLI	F	SI	ITG	II	LVILTT	QYK	TVPRF	MCNLAF	ADLCI	IYLLLI	S	IH	K												
TSHR	IVV	FVSL	LLG	VF	LLILLT	HYK	NVPRF	MCNLAF	ADFCM	MYLLLI	S	LY	H													

	<u>TM 3</u>												
LGR4	GRFAEFG	W	E	S	KV	SLA	S	SA	FL	LAAV	SVFAK	DLMKHKGSSH	QF
LGR5	GSFARHGAW	EN	V	HVI	LSI	S	FL	LAA	GFSV	KYSAKFET	APFSSL		
LHR	GQYYNHA	D	Q	S	ST	FT	L	YT	VIT	WHTITY	AIHL	DQ	LR
FSHR	SQYHNYA	D	Q	A	DA	FT	L	YT	AIT	WHTITHAM	QLDC	VQ	HA
TSHR	SEYYNHA	D	Q	P	NT	FT	L	YT	VIT	WYAITFAM	R	LD	IR

FIG. 6 (CONT)

8 8

	<u>TM 4</u>	<u>TM 5</u>
LGR4	QVAALLALLGAAVAGCF FHGGQ SASPL	FPTGETPSELGFTVTLVL SL LLMA
LGR5	KVIILLCALLALTM AV L G H GASPL	LPFGEPSTMG MVALIL SLC LMMT
LHR	ILIMLGGLFSSLI ML V V N MKVSI F	MDVETTL SQV ILTILI VV FIIC
FSHR	ASVMVMGWIFAFAA LF IF I S MKVSI	MDIDSPLSQL VMSLLV VL VVIC
TSHR	CAIMVGGWVCCFLL LL V I S AKVSI	MDTETPLALA IMFVLT IV VIVC

	<u>TM 6</u>
LGR4	II T L CNL-EKEDLSENSQSSVI HV W NCIFFC VA FSPAPLITAIS SPEI
LGR5	IA T L CNL-DKGDLENIW CSMV HI L L NCILNC VA LSF SLINLTF SPEV
LHR	AC I I FAVRNPELMATNK TKIA KM I DFTCMA IS FAI AAFKVPL TVTN
FSHR	GC IHI LTVRNPNIVSSSS TRIA RM M DFLCMA IS FAI ASLKVPL TVSK
TSHR	CCHV I ITVRNPNQYNPGDK TKIA RM V DFICMA IS YAL AILNKPL TVSN

	<u>TM 7</u>
LGR4	M SVTLI F LPA L V VF N
LGR5	I FI LVVV LPA L L IL N
LHR	S VL VL Y INS A F AI T
FSHR	A IL VL H INS A F AI T
TSHR	S IL VL Y LNS A F AI T

C-terminal tail

LGR4	PK KE WKL KRRVTRKHGSVSVSISSQGGCGEQDFYYDCGMYSHLQGNLTVCDCCESFL
LGR5	PH KE LVS RKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFTSSSITYDLPPSS
LHR	KT QR FFL LSKFGCCRRRAELYRRKDFSAITSNCKNGFTGSNKPSQSTLKLSTLHCQG
FSHR	KN RR FFI LSKGCGYEMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTVNGSTYILVPLS
TSHR	KA QR VFI LSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELI

LGR4	LTKPVSCKHLIKSHSCPVLTAASCQRPEAYWSDCGTQSAHSYADEEDSFVSDSSDQVQA
LGR5	VPSPAYPVTESCHLSSVAFVPCL
LHR	TALLDKTRYTEC
FSHR	HLAQN
TSHR	ENSHLTPKKQGQISEEYMQTVL

LGR4	CGRACFYQSRGFPLVRYAYNLQVRD
------	---------------------------

FIG. 6 (CONT)

SEQUENCE LISTING

<110> Hsuen, Aaron
 Hsu, Yu Sheau
 Liang, Chan-Guang
 van der Spek, Petrus Johannes

<120> Novel Mammalian G-Protein Coupled
 Receptors Having Extracellular Leucine Rich Repeat Regions

<130> SUN-84PCT

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2856

<212> DNA

<213> Human

<400> 1

```

atgcgcggggc cgcaggggct gctctgcttc ctgcgcctgg ggcctgcctg ctgcgcgggg      60
cccagcgggg cgcgcgcggc tctctgcggc gcgcgcctgca gctgcgcagg cgaccgtcgg      120
gtggactgct ccggaaaagg gttgacggcc gtaccggagg gtctcagcgc cttcacccaa      180
gcactggata tcagtatgaa caatatcacc cagttaccag aagatgcatt taagagtttc      240
ccattttctag aggagctaca actggctggg aacgaccttt ctcttatcca tccaaaagcc      300
ttgtctgggc tgaaagaact caaagtccta acactccaga ataatcagtt gagaacagtg      360
cccagtgaag ccattcacgg actgagtgct ttgcagtcct tacgcttaga tgccaaccat      420
attacctag tcgcggagga cagttttgaa ggccttgctc agttaagcca tctgtggctg      480
gatgacaaca gcttgacgga agtgcccggt cgtcccccctc gcaacctgcc aacctgcag      540
gcgctgacct tggctctcaa caacatctca agcatccctg acttcgcttt caccacactt      600
tcaagcttgg ttggtctgca tctgcataac aataaaaatta aaagcctcag tcaacactgt      660
tttgatggac tagataacct ggaaaccttg gacttgaatt acaattactt ggatgagttt      720
cctcaggcta ttaaagccct tcccagcctt aaagagctgg gatttcacag taattctatt      780
tctgttatte ctgatggagc atttggtggt aatccactgc taagaactat tcatttgtat      840
gataatcttc tctcttttgt ggggaactca gcatttcaca acctgtctga tctgcattgc      900
ttagtcattc gtggtgcaag cctggtgcag tgggtcccca atctgaccgg aactgtccat      960
ttggagagtc taaccttgac agggacaaaa ataagcagca tacctgatga tctgtgccaa      1020
aaccaaaaga tcttgaggac tctggactta tcttataaca atataagaga ccttccaagt      1080
tttaatgggt gtcgtgcatt ggaagaaatt tcattgcagc gtaatcaaat ctccctaata      1140
aaggaaaata cttttcaagg cctaacatct ctaaggattc tagatctgag tagaaacctg      1200
atccgtgaaa ttcacagtgg agcttttgcg aagcttggga caattactaa cctggatgta      1260
agtttcaatg aattaacttc atttcctacg gaaggcctaa atgggctcaa tcaactaaag      1320
cttgtgggta acttcaagct gaaagacgcc ttggcagcca gagactttgc taatctcagg      1380
tctctatcag taccatagc ttatcagtggt tgtgcatttt gggggtgtga ctctttatgc      1440
aaattaaaca cagaagataa cagcccccac gaacacagtg tgacaaaaga gaaaggtgct      1500
acagatgcag caaatgtcac cagcactgct gagaacgaag aacatagcca aataattatc      1560
cactgtacac cttcaacagg tgccttcaag cctgtggaat atttactggg aagctggatg      1620
attgccttta cagtgtggtt cattttcctg gtcgccttgc ttttcaacct gcttgtcatt      1680
ttaacagtggt ttgcgtcttg ttcacactg cctgcctcca aactcttcat aggtttgatt      1740
tctgtgtcta acttactcat gggcatctat actggcatcc ttacttttct tgatgctgtg      1800
tcttgggggc gatttgccga atttggcatt tgggtggaaa ctggcagcgg ctgcaaggta      1860
gccgggtctc tggcagtcct ctctcagag agcgtgttat tctattaac actggcagct      1920
gtggaaaaga gcgtatttgc aaaggatttg atgaaacacg ggaagagcag tcacctcaga      1980
cagttccagg tggccgcctt cttagctttg ctgggtgccc cagtggcagg ctgcttcccc      2040
cttttccacg gagggcaata ttctgcatcg ccttgtgttt tgccgtttcc tacaggagaa      2100

```



```

*210* 1
*211* 951
*212* PRT
  213* human

```

12

Gly	Ala	Ser	Leu	Val	Gln	Trp	Phe	Pro	Asn	Leu	Thr	Gly	Thr	Val	His
305				310						315					320
Leu	Gln	Ser	Leu	Thr	Leu	Thr	Gly	Thr	Lys	Ile	Ser	Ser	Ile	Pro	Asp
			325						330					335	
Asp	Leu	Cys	Gln	Asn	Gln	Lys	Met	Leu	Arg	Thr	Leu	Asp	Leu	Ser	Tyr
			340					345					350		
Asn	Asn	Ile	Arg	Asp	Leu	Pro	Ser	Phe	Asn	Gly	Cys	Arg	Ala	Leu	Glu
		355					360					365			
Glu	Ile	Ser	Leu	Gln	Arg	Asn	Gln	Ile	Ser	Leu	Ile	Lys	Glu	Asn	Thr
	370					375					380				
Phe	Gln	Gly	Leu	Thr	Ser	Leu	Arg	Ile	Leu	Asp	Leu	Ser	Arg	Asn	Leu
385					390					395					400
Ile	Arg	Glu	Ile	His	Ser	Gly	Ala	Phe	Ala	Lys	Leu	Gly	Thr	Ile	Thr
			405					410						415	
Asn	Leu	Asp	Val	Ser	Phe	Asn	Glu	Leu	Thr	Ser	Phe	Pro	Thr	Glu	Gly
			420					425					430		
Leu	Asn	Gly	Leu	Asn	Gln	Leu	Lys	Leu	Val	Gly	Asn	Phe	Lys	Leu	Lys
		435					440					445			
Asp	Ala	Leu	Ala	Ala	Arg	Asp	Phe	Ala	Asn	Leu	Arg	Ser	Leu	Ser	Val
	450					455					460				
Pro	Tyr	Ala	Tyr	Gln	Cys	Cys	Ala	Phe	Trp	Gly	Cys	Asp	Ser	Leu	Cys
465				470						475					480
Lys	Leu	Asn	Thr	Glu	Asp	Asn	Ser	Pro	Gln	Glu	His	Ser	Val	Thr	Lys
			485					490						495	
Glu	Lys	Gly	Ala	Thr	Asp	Ala	Ala	Asn	Val	Thr	Ser	Thr	Ala	Glu	Asn
			500					505					510		
Glu	Glu	His	Ser	Gln	Ile	Ile	Ile	His	Cys	Thr	Pro	Ser	Thr	Gly	Ala
	515						520					525			
Phe	Lys	Pro	Cys	Glu	Tyr	Leu	Leu	Gly	Ser	Trp	Met	Ile	Arg	Leu	Thr
	530					535					540				
Val	Trp	Phe	Ile	Phe	Leu	Val	Ala	Leu	Leu	Phe	Asn	Leu	Leu	Val	Ile
545					550					555					560
Leu	Thr	Val	Phe	Ala	Ser	Cys	Ser	Ser	Leu	Pro	Ala	Ser	Lys	Leu	Phe
			565					570						575	
Ile	Gly	Leu	Ile	Ser	Val	Ser	Asn	Leu	Leu	Met	Gly	Ile	Tyr	Thr	Gly
		580						585					590		
Ile	Leu	Thr	Phe	Leu	Asp	Ala	Val	Ser	Trp	Gly	Arg	Phe	Ala	Glu	Phe
		595					600					605			
Gly	Ile	Trp	Trp	Glu	Thr	Gly	Ser	Gly	Cys	Lys	Val	Ala	Gly	Ser	Leu
	610					615					620				
Ala	Val	Phe	Ser	Ser	Glu	Ser	Ala	Val	Phe	Leu	Leu	Thr	Leu	Ala	Ala
625					630					635					640
Val	Glu	Arg	Ser	Val	Phe	Ala	Lys	Asp	Leu	Met	Lys	His	Gly	Lys	Ser
			645					650						655	
Ser	His	Leu	Arg	Gln	Phe	Gln	Val	Ala	Ala	Leu	Leu	Ala	Leu	Leu	Gly
			660					665					670		
Ala	Ala	Val	Ala	Gly	Cys	Phe	Pro	Leu	Phe	His	Gly	Gly	Gln	Tyr	Ser
		675					680					685			
Ala	Ser	Pro	Leu	Cys	Leu	Pro	Phe	Pro	Thr	Gly	Glu	Thr	Pro	Ser	Leu
	690				695						700				
Gly	Phe	Thr	Val	Thr	Leu	Val	Leu	Leu	Asn	Ser	Leu	Ala	Phe	Leu	Leu
705					710					715					720
Met	Ala	Ile	Ile	Tyr	Thr	Lys	Leu	Tyr	Cys	Asn	Leu	Glu	Lys	Glu	Asp
			725					730						735	
Leu	Ser	Glu	Asn	Ser	Gln	Ser	Ser	Val	Ile	Lys	His	Val	Ala	Trp	Leu
			740					745					750		
Ile	Phe	Thr	Asn	Cys	Ile	Phe	Phe	Cys	Pro	Val	Ala	Phe	Phe	Ser	Phe
			755				760						765		


```

aaatcaccatc taaaatgccc tatgacattc attacattc cctatttaac aaacattacn 1744
tttatcagac ctcaagtaac taagtttata ctcttggttg tagtcccaact tccatcatgt 1800
ctcaatcccc ttctctacat ctgtgttcaat cctcacttta agcaggatct ggtgagccctc 1860
agaaaagcaaaa cctacgtctg gacaadaatc aaacacccaa ccttgatgtc aattaactct 1920
gatgatgtcg aaaaacagtc ctgtgaactc actcaagcct tggtaacctt taccagctcc 1980
agcatcactt aagacctgcc tcccacttcc ggcacatcac cagcttatcc agtcaactgag 2040
agctgcacac ttctctctgt ggcattttac ccatctctct aa 2082

```

<210> 4

<211> 693

<212> PRT

<213> human

<400> 4

```

Leu His Leu His Asn Asn Arg Ile His Ser Leu Gly Lys Lys Cys Phe
1          5          10          15
Asp Gly Leu His Ser Leu Glu Thr Leu Asp Leu Asn Tyr Asn Asn Leu
20          25          30
Asp Glu Phe Pro Thr Ala Ile Arg Thr Leu Ser Asn Leu Lys Glu Leu
35          40          45
Gly Phe His Ser Asn Asn Ile Arg Ser Ile Pro Glu Lys Ala Phe Val
50          55          60
Gly Asn Pro Ser Leu Ile Thr Ile His Phe Tyr Asp Asn Pro Ile Gln
65          70          75          80
Phe Val Gly Arg Ser Ala Phe Gln His Leu Pro Glu Leu Arg Thr Leu
85          90          95
Thr Leu Asn Gly Ala Ser Gln Ile Thr Glu Phe Pro Asp Leu Thr Gly
100         105         110
Thr Ala Asn Leu Glu Ser Leu Thr Leu Thr Gly Ala Gln Ile Ser Ser
115         120         125
Leu Pro Gln Thr Val Cys Asn Gln Leu Pro Asn Leu Gln Val Leu Asp
130         135         140
Leu Ser Tyr Asn Leu Leu Glu Asp Leu Pro Ser Phe Ser Val Cys Gln
145         150         155         160
Lys Leu Gln Lys Ile Asp Leu Arg His Asn Glu Ile Tyr Glu Ile Lys
165         170         175
Val Asp Thr Phe Gln Gln Leu Leu Ser Leu Arg Ser Leu Asn Leu Ala
180         185         190
Trp Asn Lys Ile Ala Ile Ile His Pro Asn Ala Phe Ser Thr Leu Pro
195         200         205
Ser Leu Ile Lys Leu Asp Leu Ser Ser Asn Leu Leu Ser Ser Phe Pro
210         215         220
Ile Thr Gly Leu His Gly Leu Thr His Leu Lys Leu Thr Gly Asn His
225         230         235         240
Ala Leu Gln Ser Trp Ile Ser Ser Glu Asn Phe Pro Glu Leu Lys Val
245         250         255
Ile Glu Met Pro Tyr Ala Tyr Gln Cys Cys Ala Phe Gly Val Cys Glu
260         265         270
Asn Ala Tyr Lys Ile Ser Asn Gln Trp Asn Lys Gly Asp Asn Ser Ser
275         280         285
Met Asp Asp Leu His Lys Lys Asp Ala Gly Met Phe Gln Ala Gln Asp
290         295         300
Glu Arg Asp Leu Glu Asp Phe Leu Leu Asp Phe Glu Glu Asp Leu Lys
305         310         315         320
Ala Leu His Ser Val Gln Cys Ser Pro Ser Pro Gly Pro Phe Lys Pro
325         330         335
Cys Glu His Leu Leu Asp Gly Trp Leu Ile Arg Ile Gly Val Trp Thr
340         345         350

```

- 210> 5
- 211> 2467
- 212> DNA
- 213> human

- 400 -

gaaaggaaga	aagaaaaaaa	anagaataga	aagaaacaga	gaagaaaaat	gggaatgaa	60
ggagggaaga	ctctttttta	actgctaaga	ttgaacacag	aaataacaca	caaccactgt	120
gagctgtatg	caatttcagaa	acaaagacaa	aatttttctc	acttttcatt	atcagtttgt	180
caatataaaa	gaaatcacat	ctagtttctt	ctctttctac	cttttaattt	ttgaaaaata	240
ttttttctcat	gggaatgagc	aggaatgcaa	atgctgcatt	ggctatttcc	cctgtgggaa	300
catcaaaaa	tactttcttc	actctctaga	ctgtaaactt	ttgaacact	ggggaatatc	360
gacccatgag	gacaactgtg	gaaacaacaa	tggatcttcc	atgcaatttg	acaaaatttt	420
tcccaattac	tacaaaaata	cttcccaata	tcattttgac	gaaaaaaaac	ctgaattttt	480

```

ggtcgattct gtgcacgtac aatctcttca ccacaggtctc gactcttact ctcatgaaa 510
caatttacga gctattccat ctttttttcc aaatctgact gcaatgtcac ttcagtgaaa 600
cttaataaga aagcttctct ctgattgctt caagaattat catgatcttc agaagctcta 690
cctgcacaaac aataagatta catccatctc catctatctt ttcagaggac tgaataaccc 780
tactaaaactg tatctcaqtc ataacagaat aacctctctg aagccgggtg tttttcaada 870
tcttcacaga ctagaatggc tgcataatca agataatcac ttcagtcgaa tttcccccac 960
aacattttat ggaataaatt ctcttctctt cttagtcttg atgaataacg tcttcaacccg 1050
tttacctgat aaacctctct gtcacacacat gccaaagata cattggctgg aacttgaaag 1140
caaccatctc cataatttaa gaaatttgc ttttatctcc tgcagtaatt taactgtttt 1230
agtgatgagg aaaaaacaaa ttaatcactt aaatgaaaat acttttgcac ctctccagaa 1320
actggatgaa ttggatttag gaagtaataa gattgaaaat tttccacccg ttatatccaa 1410
ggacctgaag gagctgtcac aattgaatct tctctataat ccaatccaga aaattcaagg 1500
aaaccaattt gattatcttg tcaaaactca gtctctcagc ctagaaggga ttgaaatttc 1590
aaatctccaa caaaggatgt tttagacctt tatgaacttc tctcacatat attttaagaa 1680
attccagtac tgggggtatg caccacatgt tggcagctgt aaacccaaac ctgattggaat 1770
ttcatctcta gagaatctct tggcaagcat tattccagaga gtatttgtct ggggttgtat 1860
tgcagttacc tgccttgga acatttttgt catttgcatg cgaccttata tcaggtctga 1950
gaacaagctg tatgccatgt caatcatttc tctctgctgt gccactgtct taatgggaat 2040
ttattttatc gtgatcggag gctttgacct aaagtctctg ggagaatata ataagcatgc 2130
gcaccttggg atggagagta ctcatcttca gcttgtagga tctttggcca tctgtctcac 2220
aqaagtatca gttttactgt taacattctt gacattggaa aaatacatct gcattgtcta 2310
tctttttaga tttgtgagac ctggaaaatg cagaacaatt acagtctctga tctctatttg 2400
tttctctgtt tttatagtgg ctctcatttc attgagcaat aaggaatttt tcaaaaaacta 2490
ctttggccac aatggagtat gcttccctct tcaatccagaa gatacagaaa gtattggagc 2580
cttgatttat tcaagtggca tttttcttgg tattaatttg gccgcattta tcatcatagt 2670
ttttctctat ggaagcatgt tttatagtgt tcaatcaagt gccataacag caactgaaat 2760
tttcaatcaa gttaaaaaag agatgatctt tggcaaacgt tttttcttta tagtatttac 2850
tcaatcaata tggctggata ccaattttgt agtgaaaatt ctctcactgc ttcaggtaga 2940
ataaccaggt accataacct ctgggttagt gatttttatt ctgcccatta acagtgtctt 3030
gaacccaatt ctctatactg tgaccacaag accattttaa gaaatgattc tcaagttttg 3120
gtataactac agacaaagaa aatctatgga cagcaaacgt cagaaaaacat atgctccatc 3210
attctctctg ggggaaatgt ggcacttcca ggagatgcca cctgagttta tgaagccgga 3300
ccttttcaca taccctctgt aatgtcact gatttctcaa tcaacgagac tcaattctta 3390
ttcatga 3480

```

<210> 6
 <211> 757
 <212> PRT
 <213> human

```

<400> 5
Met Thr Ser Gly Ser Val Phe Phe Tyr Ile Leu Ile Phe Gly Lys Tyr
1 5 10 15
Phe Ser His Gly Gly Gln Asp Val Lys Cys Ser Leu Gly Tyr Phe
20 25 30
Pro Cys Gly Asn Ile Thr Lys Cys Leu Pro Gln Leu Leu His Cys Asn
35 40 45
Gly Val Asp Asp Cys Gly Asn Gln Ala Asp Glu Asp Asn Cys Gly Asp
50 55 60
Asn Asn Gly Trp Ser Met Gln Phe Asp Lys Tyr Phe Ala Ser Tyr Tyr
65 70 75 80
Lys Met Thr Ser Gln Tyr Pro Phe Glu Ala Glu Thr Pro Glu Cys Leu
85 90 95
Val Gly Ser Val Pro Val Gln Cys Leu Cys Gln Gly Leu Glu Leu Asp
100 105 110
Cys Asp Glu Thr Asn Leu Arg Ala Val Pro Ser Val Ser Ser Asn Val
115 120 125
Thr Ala Met Ser Leu Gln Trp Asn Leu Ile Arg Lys Leu Pro Pro Asp
130 135 140

```

185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200
Leu	Ile	Thr	Ser	Ile	Ser	Ile	Tyr	Ala	Ile	Arg	Gly	Leu	Asn	Ser	Leu
205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220
Thr	Lys	Leu	Tyr	Leu	Leu	His	Asn	Arg	Ile	Thr	Phe	Leu	Lys	Ile	Gly
225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240
Val	Phe	Glu	Asp	Leu	His	Arg	Leu	Glu	Tyr	Leu	Ile	Ile	Glu	Asp	Asn
245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260
His	Leu	Ser	Arg	Ile	Ser	Ile	Ile	Thr	Ile	Tyr	Gly	Leu	Asn	Ser	Leu
265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280
Ile	Leu	Leu	Val	Leu	Met	Asn	Asn	Val	Leu	Thr	Arg	Leu	Ile	Asp	Lys
285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300
Pro	Leu	Cys	Gln	His	Met	Pro	Arg	Leu	His	Trp	Leu	Asp	Leu	Glu	Gly
305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320
Asn	His	Ile	His	Asn	Leu	Arg	Asn	Leu	Thr	Phe	Ile	Ser	Cys	Ser	Asn
325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340
Leu	Thr	Val	Leu	Val	Met	Arg	Lys	Asn	Lys	Ile	Asn	His	Leu	Asn	Glu
345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360
Asn	Thr	Phe	Ala	Pro	Leu	Gln	Lys	Leu	Asp	Glu	Leu	Asp	Leu	Gly	Ser
365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380
Asn	Lys	Ile	Glu	Asn	Leu	Pro	Pro	Leu	Ile	Phe	Lys	Asp	Leu	Lys	Glu
385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400
Leu	Ser	Gln	Leu	Asn	Leu	Ser	Tyr	Asn	Pro	Ile	Gln	Lys	Ile	Gln	Ala
405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420
Asn	Gln	Phe	Asp	Tyr	Leu	Val	Lys	Leu	Lys	Ser	Leu	Ser	Leu	Glu	Gly
425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440
Ile	Glu	Ile	Ser	Asn	Ile	Gln	Gln	Arg	Met	Phe	Arg	Pro	Leu	Met	Asn
445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460
Leu	Ser	His	Ile	Tyr	Phe	Lys	Lys	Ile	Gln	Tyr	Cys	Gly	Tyr	Ala	Pro
465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480
His	Val	Arg	Ser	Cys	Lys	Pro	Asn	Thr	Asp	Gly	Ile	Ser	Ser	Leu	Glu
485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500
Asn	Leu	Leu	Ala	Ser	Ile	Ile	Gln	Arg	Val	Phe	Val	Trp	Val	Val	Ser
505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520
Ala	Val	Thr	Cys	Phe	Gly	Asn	Ile	Phe	Val	Ile	Cys	Met	Arg	Pro	Tyr
525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540
Ile	Arg	Ser	Glu	Asn	Lys	Leu	Tyr	Ala	Met	Ser	Ile	Ile	Ser	Leu	Cys
545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560
Cys	Ala	Asp	Cys	Leu	Met	Gly	Ile	Tyr	Leu	Phe	Val	Ile	Gly	Gly	Ile
565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580
Asp	Leu	Lys	Phe	Arg	Gly	Glu	Tyr	Asn	Lys	His	Ala	Gln	Leu	Trp	Met
585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600
Glu	Ser	Thr	His	Cys	Gln	Leu	Val	Gly	Ser	Leu	Ala	Ile	Leu	Ser	Thr
605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620
Glu	Val	Ser	Val	Leu	Leu	Leu	Thr	Phe	Leu	Thr	Leu	Glu	Lys	Tyr	Ile
625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640
Cys	Ile	Val	Tyr	Pro	Phe	Arg	Cys	Val	Arg	Pro	Gly	Lys	Cys	Arg	Thr
645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660
Ile	Thr	Val	Leu	Ile	Leu	Ile	Trp	Ile	Thr	Gly	Phe	Ile	Val	Ala	Phe
665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680
Ile	Pro	Leu	Ser	Asn	Lys	Glu	Phe	Phe	Lys	Asn	Tyr	Tyr	Gly	Thr	Asn
685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700
Gly	Val	Cys	Phe	Pro	Leu	His	Ser	Glu	Asp	Thr	Glu	Ser	Ile	Gly	Ala
705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720
Gln	Ile	Tyr	Ser	Val	Ala	Ile	Phe	Leu	Gly	Ile	Asn	Leu	Ala	Ala	Phe
725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740
Ile	Ile	Ile	Val	Phe	Ser	Tyr	Gly	Ser	Met	Phe	Tyr	Ser	Val	His	Gln

Ser Ala Ile Thr Ala Thr Glu Ile Arg Asn Gln Val Lys Lys Glu Met
 610 615 620
 Ile Leu Ala Lys Arg Phe Phe Phe Ile Val Phe Thr Asp Ala Leu Cys
 625 630 635 640
 Trp Ile Pro Ile Phe Val Val Lys Phe Leu Ser Leu Leu Gln Val Glu
 645 650 655
 Ile Pro Gly Thr Ile Thr Ser Trp Val Val Ile Phe Ile Leu Pro Ile
 660 665 670
 Asn Ser Ala Leu Asn Pro Ile Leu Tyr Thr Leu Thr Thr Arg Pro Phe
 675 680 685
 Lys Glu Met Ile His Arg Phe Trp Tyr Asn Tyr Arg Gln Arg Lys Ser
 690 695 700
 Met Asp Ser Lys Gly Gln Lys Thr Tyr Ala Pro Ser Phe Ile Trp Val
 705 710 715 720
 Glu Met Trp Pro Leu Gln Glu Met Pro Pro Glu Leu Met Lys Pro Asp
 725 730 735
 Leu Phe Thr Tyr Pro Cys Glu Met Ser Leu Ile Ser Gln Ser Thr Arg
 740 745 750
 Leu Asn Ser Tyr Ser
 755

<210> 7
 <211> 3584
 <212> DNA
 <213> human

<400> 7
 ctgctttgta actgctaaga ttgcagacag aaatagcaca caaccactgt gagctgtatg 60
 cgattcagaa accaagacca aattttgtct acttttcatta atcagtttgt cagatagaag 120
 gaaatgacat ctggttctgt ottcttctac atcttaattt ttggaaaata tttttctcat 180
 gggggtggac aggatgtcaa gtgtccctt ggctatttcc cctgtgggaa catcacaaag 240
 tgcttgcttc agctcctgca ctgtaacggt gtggacgact gcgggaatca ggccgatgag 300
 gacaactgtg tgggtggttt gtgccagtgc atgtctttgc caggtctgga gcttgactgg 360
 atgaaaccat ttacgagtgt tccatcgggt tcttcaaattg tgaactgcaat gtcacttcag 420
 tggaacttaa taagaaagct tctcctgat tgcttcaaga attatcatga tcttcagaag 480
 ctggacctgc aaaacaataa gattacatcc atctccatct atgctttcag aggactgaat 540
 agccttacta aactgtatct cagtcataac agaataacct tctgaagcc gggtgttttt 600
 gaagatcttc acagactaga atggttgata attgaagata atcacctcag tgaattttcc 660
 ccaccaacat tttatggact aaattctctt attctcttag tctgatgaa taacgtcttc 720
 accggtttac ctgataaaac tctctgtcaa cacatgccaa gactacattg gctggacctt 780
 gaaggcaaac atatccataa ttaagaaat ttgactttta tttctgcag taatttaact 840
 gtttttagtga tgaggaaaaa caaaattaat cacttaaatg aaaatacttt tgcacctctc 900
 cagaaactgg atgaattgga tttaggaagt aataagattg aaaatcttcc accgcttata 960
 ttcaaggacc tgaaggagt gtccacaattg aatctttcct ataatccaat ccagaaaatt 1020
 caagcaaac aaattgatta tcttgtaaaa ctcaagtctc tcagcctaga agggattgaa 1080
 atttcaataa tccaacaaag gatgtttaga cctcttatga atctctctca catatatattt 1140
 aagaaattcc agtactgtgg gtatgcacca catgttcgca gctgtaaacc aaacactgat 1200
 ggaatttcct ctctagagaa tctcttggca agcattatcc agagagtatt tgtctgggtt 1260
 gtatctgcag ttacctgctt tggaaacatt ttgtctattt gcatgcgacc ttatatcagg 1320
 tctgagaaca agctgtatgc catgtcaate atttctctct gctgtgccga ctgcttaattg 1380
 ggaataattt tattcgtgat oggaggtctt gacctaaagt ttctgtgaga atacaataag 1440
 catgcgcagc tgtggatgga gagtactcat gtgcagcttg taggatcttt ggccattctg 1500
 tccacagaag tatcagtttt actgttaaca tttctgacat tggaaaaata catctgcatt 1560
 gtctatcctt ttagatgtgt gagacctgga aaatgcagaa caattacagt tctgattctc 1620
 atttgatta ctggttttat agtggctttc attccattga gcaataagga atttttcaaa 1680
 aactactatg gcaccaatgg agtatgcttc cctcttcatt cagaagatac agaaagtatt 1740
 ggagcccaga tttattcagt ggcaattttt cttgggtatta atttggccgc atttatcact 1800
 atagtttttt cctatggaag catgttttat agtgttctac aaagtccat aacagcaact 1860
 gaaatacggg atcaagttaa aaaagagatg atccttgcca aacgtttttt ctttatagta 1920


```

cttactatata cacttatctta cttatccatt tttttatnta aatttttllt tttttttcag 1930
atagaaatac caggttaccat aacctctttag ctatctcatt ttatctctac ttttaacagt 1940
cttttgaacc caattctctt tactctctacc acaagaccaa ttaaaacaaat ttttctatgg 2100
cttttggtata tctacagaca aaaaaaatct atggacacaa aagctcagaa aactatgtct 2150
ccatcattca tcttggtgga tctcttcccc ctccagagaa tgcacacctc cttaaatdaad 2220
caggaccttt tccacatacc ctctgaatat tcaatcattt ctcaatcaac cagctcaat 2230
tcttatctca cactcactct gaaattccat tcttgagaga caatactctg gggctgcttc 2340
atdagggatt tacttggtat aaaaatcaata ccacaaaaat aattttataa tatadctaag 2400
ataaaatattt tacaaggaca tgaagaaaaa taaaaatgac taactctctt ccaagaggaa 2450
gtaatttatat caataatctt tctatattac tagacatttt gtttaaaaaa ttaagagaaaa 2520
tctacttcag taacattcat tcatctttct aacatgcatt tattgactac ccactattat 2530
gtgcatagca ttgcaatata gtcttggaag tagacagtgc agaacttttc aatctgtaga 2640
tagtgttttaa tgcacaaaaga ctatacaaaag tccatctgca gttctctatt taaagttagag 2700
ctttacctgt catgtgcac accaagaatc ataggcaact ttaaaataaag tttttaaagt 2760
ttggaatact cagtgtattt ccatcataga aaatgtctga ctgttttcaa aataatattc 2820
tgttttaaga atccatctta cctctcttta agtttccata cacttgagag ccaacacaac 2880
atattttatta ctaaaaagat cctttgctag aaactcaaaa acagcaacttc ttttggaact 2940
tctctcccaa ttttctcttt cttttaaatc aacatcatca tatcgaattc caataaggaa 3000
gtatgagtag ggcagagaaq tggatcagaa aaactagaat gaggataaac atttacatta 3060
gtggaaaactc ctgaaaaata tcttcttatt gtcagttaac tgattttcaa caaggatgcc 3120
aagacaaaaa ggcttttcaa caaacctgtc tgttttaaga acagaactaa gtggtttaat 3180
ccaccacatt tagatgggtg aatgtttatg tgtgtgaaat atctcagtaa agcagttaaa 3240
aggaaaaaja gcttggaatgc actgattcag gaacttaatt tccggaagga aaggtctgta 3300
tgtacacatt tcactttaag cagaaaaatc ttcttcaaga aatgacttta ctttctcttt 3360
gcactgcccag caagttagat actaactttt taactagttg ttctctctta gtctctacgt 3420
tattagnatt ttttgctttc ataattgtga acctttaagc aggagaagaa aatdttttca 3480
gatagtttca aatacnccaa aaatgtttgc aacacaaaaa tactggaatc naaccataat 3540
gaccttattg aatatatagt tgtatagntt tgtttgaaa aacc 3584

```

<210> 8

<211> 722

<212> PRT

<213> human

<400> 8

```

Met Thr Ser Gly Ser Val Phe Phe Tyr Ile Leu Ile Phe Gly Lys Tyr
1           5           10           15
Phe Ser His Gly Gly Gly Gln Asp Val Lys Cys Ser Leu Gly Tyr Phe
20          25          30
Pro Cys Gly Asn Ile Thr Lys Cys Leu Pro Gln Leu Leu His Cys Asn
35          40          45
Gly Val Asp Asp Cys Gly Asn Gln Ala Asp Glu Asp Asn Cys Val Val
50          55          60
Val Leu Cys Gln Cys Met Ser Leu Pro Gly Leu Glu Leu Asp Trp Met
65          70          75          80
Lys Pro Phe Thr Ser Val Pro Ser Val Ser Ser Asn Val Thr Ala Met
85          90          95
Ser Leu Gln Trp Asn Leu Ile Arg Lys Leu Pro Pro Asp Cys Phe Lys
100         105         110
Asn Tyr His Asp Leu Gln Lys Leu Asp Leu Gln Asn Asn Lys Ile Thr
115         120         125
Ser Ile Ser Ile Tyr Ala Phe Arg Gly Leu Asn Ser Leu Thr Lys Leu
130         135         140
Tyr Leu Ser His Asn Arg Ile Thr Phe Leu Lys Pro Gly Val Phe Glu
145         150         155         160
Asp Leu His Arg Leu Glu Trp Leu Ile Ile Glu Asp Asn His Leu Ser
165         170         175
Arg Ile Ser Pro Pro Thr Phe Tyr Gly Leu Asn Ser Leu Ile Leu Leu
180         185         190

```

Val	Leu	Met	Asn	Asn	Val	Leu	Thr	Arg	Leu	Trp	Asp	Lys	Trp	Leu	Cys
191															
Gln	His	Met	Trp	Arg	Leu	His	Trp	Leu	Asp	Leu	Gln	Gly	Asn	His	Ile
210															
His	Asn	Leu	Arg	Asn	Leu	Thr	Phe	Ile	Ser	Cys	Ser	Asn	Leu	Thr	Val
221															
Leu	Val	Met	Arg	Lys	Asn	Lys	Ile	Asn	His	Leu	Asn	Glu	Asn	Thr	Phe
Ala	Pro	Leu	Gln	Lys	Leu	Asp	Glu	Leu	Asp	Leu	Gly	Ser	Asn	Lys	Ile
Glu	Asn	Leu	Pro	Pro	Leu	Ile	Phe	Lys	Asp	Leu	Lys	Glu	Leu	Ser	Gln
Leu	Asn	Leu	Ser	Tyr	Asn	Pro	Ile	Gln	Lys	Ile	Gln	Ala	Asn	Gln	Phe
Asp	Tyr	Leu	Val	Lys	Leu	Lys	Ser	Leu	Ser	Leu	Glu	Gly	Ile	Glu	Ile
305															
Ser	Asn	Ile	Gln	Gln	Arg	Met	Phe	Arg	Pro	Leu	Met	Asn	Leu	Ser	His
Ile	Tyr	Phe	Lys	Lys	Phe	Gln	Tyr	Cys	Gly	Tyr	Ala	Pro	His	Val	Arg
Ser	Cys	Lys	Pro	Asn	Thr	Asp	Gly	Ile	Ser	Ser	Leu	Glu	Asn	Leu	Leu
Ala	Ser	Ile	Ile	Gln	Arg	Val	Phe	Val	Trp	Val	Val	Ser	Ala	Val	Thr
Cys	Phe	Gly	Asn	Ile	Phe	Val	Ile	Cys	Met	Arg	Pro	Tyr	Ile	Arg	Ser
385															
Glu	Asn	Lys	Leu	Tyr	Ala	Met	Ser	Ile	Ile	Ser	Leu	Cys	Cys	Ala	Asp
Cys	Leu	Met	Gly	Ile	Tyr	Leu	Phe	Val	Ile	Gly	Gly	Phe	Asp	Leu	Lys
Phe	Arg	Gly	Glu	Tyr	Asn	Lys	His	Ala	Gln	Leu	Trp	Met	Glu	Ser	Thr
His	Cys	Gln	Leu	Val	Gly	Ser	Leu	Ala	Ile	Leu	Ser	Thr	Glu	Val	Ser
450															
Val	Leu	Leu	Leu	Thr	Phe	Leu	Thr	Leu	Glu	Lys	Tyr	Ile	Cys	Ile	Val
465															
Tyr	Pro	Phe	Arg	Cys	Val	Arg	Pro	Gly	Lys	Cys	Arg	Thr	Ile	Thr	Val
Leu	Ile	Leu	Ile	Trp	Ile	Thr	Gly	Phe	Ile	Val	Ala	Phe	Ile	Pro	Leu
Ser	Asn	Lys	Glu	Phe	Phe	Lys	Asn	Tyr	Tyr	Gly	Thr	Asn	Gly	Val	Cys
Phe	Pro	Leu	His	Ser	Glu	Asp	Thr	Glu	Ser	Ile	Gly	Ala	Gln	Ile	Tyr
530															
Ser	Val	Ala	Ile	Phe	Leu	Gly	Ile	Asn	Leu	Ala	Ala	Phe	Ile	Ile	Ile
545															
Val	Phe	Ser	Tyr	Gly	Ser	Met	Phe	Tyr	Ser	Val	His	Gln	Ser	Ala	Ile
Thr	Ala	Thr	Glu	Ile	Arg	Asn	Gln	Val	Lys	Lys	Glu	Met	Ile	Leu	Ala
Lys	Arg	Phe	Phe	Phe	Ile	Val	Phe	Thr	Asp	Ala	Leu	Cys	Trp	Ile	Pro
Ile	Phe	Val	Val	Lys	Phe	Leu	Ser	Leu	Leu	Gln	Val	Glu	Ile	Pro	Gly
610															
Thr	Ile	Thr	Ser	Trp	Val	Val	Ile	Phe	Ile	Leu	Pro	Ile	Asn	Ser	Ala
625															
Leu	Asn	Pro	Ile	Leu	Tyr	Thr	Leu	Thr	Thr	Arg	Pro	Phe	Lys	Glu	Met

```

Ile His Arg Ihe Trp Tyr Asn Tyr Arg Glu Arg Lys Ser Met Asp Ser
666
Lys Gly Glu Lys Thr Tyr Ala Pro Ser Ihe Ile Trp Val Glu Met Trp
675
Pro Leu Glu Glu Met Pro Pro Glu Leu Met Lys Pro Asp Leu Phe Thr
680
Tyr Pro Cys Glu Met Ser Leu Ile Ser Glu Ser Thr Arg Leu Asn Ser
690
Tyr Ser
700
710
720

```

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06573

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/705; C12N 15/12, 15/63, 15/70, 15/79

US CL : 530/350; 435/69.1, 252.3, 254.11, 320.1, 325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 435/69.1, 252.3, 254.11, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Biosis, Medline, WPI

search terms: G-protein coupled receptor, Leucine rich repeats, Gonadotropin receptor, Thyrotropin receptor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,614,363 A (CONE) 25 March 1997, entire document.	1-11
X, P ----- Y, P	US 5,858,716 A (ELSHOURBAGY et al.) 12 January 1999, columns 20-30, entire document.	11 ----- 1-10
X -- Y	HWANG et al. Analysis of Expressed Sequence Tags from a Fetal Human Heart cDNA Library. Genomics. 1995, Vol. 30, pages 293-298, entire document.	5, 7, 11 ----- 1-4, 6, 8-10

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 JUNE 1999

Date of mailing of the international search report

02 AUG 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Sally P. Teng

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No
PCT/US99/06573

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows.

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to nucleic acids encoding LGR4, the LGR4 polypeptide, and method of using the LGR4 nucleic acid.

Group II, claims 1-11, drawn to nucleic acids encoding LGR5, the LGR5 polypeptide and method of using the LGR5 nucleic acid.

Group III, claims 1-11, drawn to nucleic acid encoding LGR6, the LGR6 polypeptide, and method of using the LGR6 nucleic acid.

Group IV, claims 12 and 13, drawn to antibody that binds to LGR4.

Group V, claims 12 and 13, drawn to antibody that binds to LGR5.

Group VI, claims 12 and 13, drawn to antibody that binds to LGR7.

Group VII, claims 14-17, drawn to transgenic animal model containing an altered LGR4 gene.

Group VIII, claims 14-17, drawn to transgenic animal model containing an altered LGR5 gene

Group IX, claims 14-17, drawn to transgenic animal model containing an altered LGR7 gene

Group X, claim 18, drawn to a method of screening for a ligand for LGR4.

Group XI, claim 18, drawn to a method of screening for a ligand for LGR5.

Group XII, claim 18, drawn to a method of screening for a ligand for LGR7.

Each of the claims 1-18 is in three different groups because LGR4, LGR5, and LGR7 are structurally and functionally distinct polypeptides.

The inventions listed as Groups I-XII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is the nucleic acid sequence encoding LGR4. The special technical feature of Group II is the nucleic acid sequence encoding LGR5. The special technical feature of Group III is the nucleic acid sequence encoding LGR7. The special technical feature of Group IV is the antibody that binds to LGR4 but does not have the amino acid sequence of LGR4. The special technical feature of Group V is the antibody that binds to LGR5 but does not have the amino acid sequence of LGR5. The special technical feature of Group VI is the antibody that binds to LGR6 but does not have the amino acid sequence of LGR6. The special technical feature of Group VII is a transgenic animal containing an altered LGR4 gene. The special technical feature of Group VIII is a transgenic animal containing an altered LGR5 gene. The special technical feature of Group IX is a transgenic animal containing an altered LGR7 gene. The special technical feature of Group X is a method of screening for a ligand that binds LGR4. The special technical feature of Group XI is a method of screening for a ligand that binds LGR5. The special technical feature of Group XII is a method of screening for a ligand that binds LGR7. The special technical feature of each group is not the same or does not correspond to the special technical feature of any other group because the products of Groups I-IX are structurally and functionally distinct and the methods of Groups I-III and X-XII are distinct methods of using different starting reagent for accomplishing different goals. The groups are not linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06573

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	HSU et al. Characterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracellular Leucine-Rich Repeats and a G Protein-Coupled, Seven Transmembrane Region. Molecular Endocrinology. December 1998, Vol. 12, No. 12, pages 1830-1845, especially pages 1831-1837.	1-11